BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429-442. [PMID: 12540794 DOI: 10.1053/jhep.2003.50047] [Cited by in Crossref: 2017] [Cited by in F6Publishing: 1839] [Article Influence: 106.2] [Reference Citation Analysis]
Number Citing Articles
1 Stevens CL, Awad A, Abbas SM, Watters DAK. Systematic review and meta-analysis of hepatic resection versus transarterial chemoembolization for solitary large hepatocellular carcinoma. HPB (Oxford) 2017;19:653-8. [PMID: 28427829 DOI: 10.1016/j.hpb.2017.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
2 Zhou Y, Wang Y, Zhou W, Chen T, Wu Q, Chutturghoon VK, Lin B, Geng L, Yang Z, Zhou L, Zheng S. YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. Cancer Cell Int 2019;19:179. [PMID: 31337986 DOI: 10.1186/s12935-019-0898-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 9.7] [Reference Citation Analysis]
3 Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681-700. [PMID: 26484443 DOI: 10.1038/nrgastro.2015.173] [Cited by in Crossref: 252] [Cited by in F6Publishing: 262] [Article Influence: 36.0] [Reference Citation Analysis]
4 Sun Z, Li G, Ai X, Luo B, Wen Y, Zhao Z, Dong S, Guan J. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol 2011;79:164-74. [PMID: 20719529 DOI: 10.1016/j.critrevonc.2010.07.019] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
5 Welker MW, Trojan J. Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives. World J Gastroenterol 2011; 17(26): 3075-3081 [PMID: 21912449 DOI: 10.3748/wjg.v17.i26.3075] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
6 Sun L, Fahey P, Zhu X, Ng W, Chen ZP, Qiu Y, Lai H, Lin J, Lin L. A Cohort Study to Examine the Use of Chinese Herbal Medicine in Combination With Conventional Therapies for Patients With Hepatocellular Carcinoma in China. Integr Cancer Ther 2018;17:902-11. [PMID: 29775121 DOI: 10.1177/1534735418775819] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
7 Russo MW. Current concepts in the evaluation of patients for liver transplantation. Expert Review of Gastroenterology & Hepatology 2014;1:307-20. [DOI: 10.1586/17474124.1.2.307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Zhou B, Shan H, Zhu KS, Jiang ZB, Guan SH, Meng XC, Zeng XC. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Vasc Interv Radiol. 2010;21:333-338. [PMID: 20116286 DOI: 10.1016/j.jvir.2009.11.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
9 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
10 Altomonte J, Braren R, Schulz S, Marozin S, Rummeny EJ, Schmid RM, Ebert O. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 2008;48:1864-73. [PMID: 19003878 DOI: 10.1002/hep.22546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
11 Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, Marin JJ, Briz O. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology. 2013;58:1065-1073. [PMID: 23532667 DOI: 10.1002/hep.26425] [Cited by in Crossref: 79] [Cited by in F6Publishing: 133] [Article Influence: 8.8] [Reference Citation Analysis]
12 Llovet JM, Bruix J. Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. Radiology. 2004;230:300-31; author reply 300-301;. [PMID: 14695404 DOI: 10.1148/radiol.2301030753] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
13 Khorsandi SE, Heaton N. Contemporary strategies in the management of hepatocellular carcinoma. HPB Surg 2012;2012:154056. [PMID: 23197879 DOI: 10.1155/2012/154056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
14 Scanga A, Kowdley K, Kowdley K, Mccaughan G, Trautwein C. Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma? Hepatology 2009;49:332-4. [DOI: 10.1002/hep.22756] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
15 Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010;116:4590-4596. [PMID: 20572033 DOI: 10.1002/cncr.25257] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 9.2] [Reference Citation Analysis]
16 Frangakis C, Geschwind JF, Kim D, Chen Y, Koteish A, Hong K, Liapi E, Georgiades CS. Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list. Cardiovasc Intervent Radiol. 2011;34:1254-1261. [PMID: 21191590 DOI: 10.1007/s00270-010-0077-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
17 Hoofnagle JH. Hepatocellular carcinoma: summary and recommendations. Gastroenterology 2004;127:S319-23. [PMID: 15508100 DOI: 10.1053/j.gastro.2004.09.047] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
18 Pan JJ, Javle M, Thinn MM, Hsueh CT, Hsueh CT. Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepat Med 2010;2:147-55. [PMID: 24367212 DOI: 10.2147/HMER.S7123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
19 Wang HQ, Yang JY, Yan LN. Hemihepatic versus total hepatic inflow occlusion during hepatectomy: A systematic review and meta-analysis. World J Gastroenterol 2011; 17(26): 3158-3164 [PMID: 21912460 DOI: 10.3748/wjg.v17.i26.3158] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
20 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
21 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 494] [Article Influence: 160.7] [Reference Citation Analysis]
22 Lee SJ, Hwang JW, Yim H, Yim HJ, Woo SU, Suh SJ, Hyun JJ, Jung SW, Koo JS, Kim JH, Seo YS, Yeon JE, Lee SW, Byun KS, Um SH. Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line. J Gastroenterol Hepatol 2014;29:1299-307. [PMID: 24372723 DOI: 10.1111/jgh.12503] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
23 Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology. 2004;127:S218-S224. [PMID: 15508087 DOI: 10.1053/j.gastro.2004.09.036] [Cited by in Crossref: 175] [Cited by in F6Publishing: 166] [Article Influence: 9.7] [Reference Citation Analysis]
24 Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. [PMID: 19908093 DOI: 10.1007/s00270-099-9711-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol 2005;43:584-9. [PMID: 16120468 DOI: 10.1016/j.jhep.2005.07.019] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
26 Abe T, Saitoh J, Kobayashi D, Shibuya K, Koyama Y, Shimada H, Shirai K, Ohno T, Nakano T. Dosimetric comparison of carbon ion radiotherapy and stereotactic body radiotherapy with photon beams for the treatment of hepatocellular carcinoma. Radiat Oncol. 2015;10:187. [PMID: 26377092 DOI: 10.1186/s13014-015-0491-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
27 Fan HL, Hsieh CB, Chang WC, Huang SH, Chan DC, Yu JC, Chu CH, Chen TW. Advanced age is not a contraindication for liver resection in cases of large hepatocellular carcinoma. Eur J Surg Oncol 2014;40:214-9. [PMID: 24316111 DOI: 10.1016/j.ejso.2013.10.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
28 Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability. Ann Surg Oncol. 2007;14:3301-3309. [PMID: 17891443 DOI: 10.1245/s10434-007-9549-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
29 Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant. 2008;8:839-846. [PMID: 18318783 DOI: 10.1111/j.1600-6143.2007.02138.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 128] [Article Influence: 9.6] [Reference Citation Analysis]
30 Malbranche C, Boulin M, Guiu B, Pernot C, Cercueil J, Serge Aho L, Musat A, Bedenne L, Hillon P, Guignard M, Fagnoni P. Impact économique de la chimioembolisation avec microsphères chargées dans le traitement du carcinome hépatocellulaire. Bulletin du Cancer 2011;98:671-8. [DOI: 10.1684/bdc.2011.1370] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
31 Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24:307-315. [PMID: 23375519 DOI: 10.1016/j.jvir.2012.11.026] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
32 Mitchell JW, O'Connell WG, Kisza P, Klyde DP, Gonzalez SF, Maldjian P, Bahramipour P, Contractor SG. Safety and feasibility of outpatient transcatheter hepatic arterial embolization for hepatocellular carcinoma. J Vasc Interv Radiol 2009;20:203-8. [PMID: 19097805 DOI: 10.1016/j.jvir.2008.10.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
33 Matsuda Y, Fukumoto M. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 2011;44:183-9. [PMID: 22179180 DOI: 10.1007/s00795-011-0558-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
34 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 130.2] [Reference Citation Analysis]
35 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:159-69. [DOI: 10.1038/ncpgasthep1357] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
36 Sonoda A, Nitta N, Ohta S, Nitta-Seko A, Nagatani Y, Takahashi M, Murata K. Enhanced antitumor effect of tirapazamine delivered intraperitoneally to VX2 liver tumor-bearing rabbits subjected to transarterial hepatic embolization. Cardiovasc Intervent Radiol 2011;34:1272-7. [PMID: 21479745 DOI: 10.1007/s00270-011-0156-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
37 Riemsma RP, Bala MM, Wolff R, Kleijnen J. Electro-coagulation for liver metastases. Cochrane Database Syst Rev 2013;:CD009497. [PMID: 23728692 DOI: 10.1002/14651858.CD009497.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Lubienski A. Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation. 2005;80:S113-S119. [PMID: 16286887 DOI: 10.1097/01.tp.0000187109.69663.93] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
39 Maluccio MA, Covey AM, Porat LB, Schubert J, Brody LA, Sofocleous CT, Getrajdman GI, Jarnagin W, Dematteo R, Blumgart LH, Fong Y, Brown KT. Transcatheter Arterial Embolization with Only Particles for the Treatment of Unresectable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2008;19:862-9. [DOI: 10.1016/j.jvir.2008.02.013] [Cited by in Crossref: 110] [Cited by in F6Publishing: 105] [Article Influence: 7.9] [Reference Citation Analysis]
40 Ruiz I, Féray C. [Current management of hepatocellular carcinoma]. Cancer Radiother 2015;19:410-5. [PMID: 26337474 DOI: 10.1016/j.canrad.2015.05.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
41 Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Yu D, Meyer T, Patch DW, Burroughs AK. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006;32:594-606. [PMID: 17045407 DOI: 10.1016/j.ctrv.2006.08.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
42 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
43 Liu T, Hwang T, Park B, Bell J, Kirn DH. The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma. Molecular Therapy 2008;16:1637-42. [DOI: 10.1038/mt.2008.143] [Cited by in Crossref: 131] [Cited by in F6Publishing: 129] [Article Influence: 9.4] [Reference Citation Analysis]
44 Butt AS, Mujtaba G, Anand S, Krishnaiah M. Management of biliopleural fistula after transarterial chemoembolization of a liver lesion. Can J Gastroenterol 2010;24:281-3. [PMID: 20485700 DOI: 10.1155/2010/790726] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
45 Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, Tong MJ, Britten CD, Busuttil RW. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. AJR Am J Roentgenol 2017;209:722-32. [PMID: 28705059 DOI: 10.2214/AJR.17.18219] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
46 Chang PY, Huang CC, Hung CH, Yu CY, Wu DK, Hwang JI, Liang PC, Wu RH, Tsai WL, Lin YJ, Liu YS, Liang HL, Lee RC, Chen CH. Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. Liver Cancer 2018;7:312-22. [PMID: 30488021 DOI: 10.1159/000487608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Belghiti J, Carr BI, Greig PD, Lencioni R, Poon RT. Treatment before liver transplantation for HCC. Ann Surg Oncol. 2008;15:993-1000. [PMID: 18236111 DOI: 10.1245/s10434-007-9787-8] [Cited by in Crossref: 82] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
48 Zhen MC, Wang FQ, Wu SF, Zhao YL, Liu PG, Yin ZY. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells. Oncotarget 2017;8:9466-75. [PMID: 28036295 DOI: 10.18632/oncotarget.14326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Li J, Liu W, Zhu W, Wu Y, Wu B. Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. Oncotarget. 2017;8:59601-59608. [PMID: 28938663 DOI: 10.18632/oncotarget.19334] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
50 Liu YS, Ou MC, Tsai YS, Lin XZ, Wang CK, Tsai HM, Chuang MT. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. Korean J Radiol. 2015;16:125-132. [PMID: 25598680 DOI: 10.3348/kjr.2015.16.1.125] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
51 Liu F, Zhang W, Yang F, Feng T, Zhou M, Yu Y, Yu X, Zhao W, Yi F, Tang W. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Sci Rep. 2016;6:21260. [PMID: 26879559 DOI: 10.1038/srep21260] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
52 Kitisin K, Packiam V, Steel J, Humar A, Gamblin TC, Geller DA, Marsh JW, Tsung A. Presentation and outcomes of hepatocellular carcinoma patients at a western centre. HPB (Oxford) 2011;13:712-22. [PMID: 21929672 DOI: 10.1111/j.1477-2574.2011.00362.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
53 Sebastian NT, Miller ED, Yang X, Diaz DA, Tan Y, Dowell J, Spain J, Rikabi A, Elliott E, Knopp M, Williams TM. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2020;108:1276-83. [PMID: 32712254 DOI: 10.1016/j.ijrobp.2020.07.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
54 Hiatt JR, Carmody IC, Busuttil RW. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?--no, never. J Hepatol 2005;43:573-7. [PMID: 16112768 DOI: 10.1016/j.jhep.2005.07.017] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
55 Arslan M, Degirmencioglu S. Risk Factors for Postembolization Syndrome After Transcatheter Arterial Chemoembolization. Curr Med Imaging Rev. 2019;15:380-385. [PMID: 31989907 DOI: 10.2174/1573405615666181122145330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
56 Bala MM, Riemsma RP, Wolff R, Kleijnen J; Cochrane Hepato-Biliary Group. Transarterial (chemo)embolisation versus other nonsurgical ablation methods for liver metastases. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd010588] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
57 Youn BJ, Chung JW, Son KR, Kim H, Jae HJ, Lee JM, Song IC, Kim I, Park JH. Diffusion-Weighted MR. Academic Radiology 2008;15:593-600. [DOI: 10.1016/j.acra.2007.10.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
58 Podnos YD, Wagman LD. The Surgeon and Palliative Care. Ann Surg Oncol 2007;14:1257-63. [DOI: 10.1245/s10434-006-9222-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
59 Escarda A, Vaquer P, Bonet L, Miralbés S, Gómez C, Obrador A. [Clivus metastasis from hepatocarcinoma associated with transarterial hepatic chemoembolization]. Gastroenterol Hepatol 2006;29:401-4. [PMID: 16938255 DOI: 10.1157/13091453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
60 Abdel-hamid NM, Nazmy MH, Abdel-ghany MI, Nazmy WH. Cytokines as important playmakers of experimental hepatocarcinogenesis confounded by diabetes. Annals of Hepatology 2012;11:118-27. [DOI: 10.1016/s1665-2681(19)31495-4] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
61 Zhang ZQ, Xiong L, Zhou JJ, Miao XY, Li QL, Wen Y, Zou H. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC. World J Surg Oncol. 2018;16:208. [PMID: 30326907 DOI: 10.1186/s12957-018-1500-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
62 Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLoS One 2020;15:e0240542. [PMID: 33052942 DOI: 10.1371/journal.pone.0240542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
63 Tsochatzis EA, Germani G, Burroughs AK. Transarterial Chemoembolization, Transarterial Chemotherapy, and Intra-arterial Chemotherapy for Hepatocellular Carcinoma Treatment. Seminars in Oncology 2010;37:89-93. [DOI: 10.1053/j.seminoncol.2010.03.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
64 Burroughs A, Samonakis D. Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma? Nat Rev Gastroenterol Hepatol 2004;1:78-9. [DOI: 10.1038/ncpgasthep0038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
65 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:354-362. [PMID: 22083023 DOI: 10.1016/j.cgh.2011.11.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
66 Guo Y, Tan EK, Syn NL, Krishnamoorthy TL, Tan CK, Lim R, Lee SY, Chan CY, Cheow PC, Chung AYF, Jeyaraj PR, Goh BKP. Repeat liver resection vs salvage liver transplant for recurrent hepatocellular carcinoma: A propensity score-adjusted and -matched comparison analysis. Ann Hepatobiliary Pancreat Surg. 2019;23:305-312. [PMID: 31824994 DOI: 10.14701/ahbps.2019.23.4.305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
67 Lv H, Zhang Z, Wu X, Wang Y, Li C, Gong W, Gui L, Wang X. Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent. PLoS One 2016;11:e0145195. [PMID: 26727592 DOI: 10.1371/journal.pone.0145195] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
68 Lee MW, Kim YJ, Park HS, Yu NC, Jung SI, Ko SY, Jeon HJ. Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. AJR Am J Roentgenol. 2010;194:W396-W400. [PMID: 20410384 DOI: 10.2214/ajr.09.3171] [Cited by in Crossref: 66] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
69 Wang J, Yang T, Chen H, Li H, Zheng S. Oncogene RPA1 promotes proliferation of hepatocellular carcinoma via CDK4/Cyclin-D pathway. Biochem Biophys Res Commun 2018;498:424-30. [PMID: 29477843 DOI: 10.1016/j.bbrc.2018.02.167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
70 Mueller PP, Chen Q, Ayer T, Nemutlu G, Hajjar A, Bethea ED, Peters MLB, Lee BP, Janjua NZ, Kanwal F, Chhatwal J. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.027] [Reference Citation Analysis]
71 Woo HY, Heo J. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future. Clin Mol Hepatol. 2015;21:344-348. [PMID: 26770921 DOI: 10.3350/cmh.2015.21.4.344] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
72 Wu Y, Qi H, Cao F, Shen L, Chen S, Xie L, Huang T, Song Z, Zhou D, Fan W. TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma. Front Pharmacol 2020;11:1130. [PMID: 32903854 DOI: 10.3389/fphar.2020.01130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Son SH, Park EY, Park HH, Kay CS, Jang HS. Pre-radiotherapy neutrophil-to-lymphocyte ratio as an independent prognostic factor in patients with locally advanced hepatocellular carcinoma treated with radiotherapy. Oncotarget. 2017;8:16964-16971. [PMID: 28199977 DOI: 10.18632/oncotarget.15209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
74 Huang YK, Yen CL, Shiu SI, Lee SW, Chang PY, Yeh HZ, Lee TY. Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma. PLoS One 2017;12:e0188999. [PMID: 29190692 DOI: 10.1371/journal.pone.0188999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
75 Wang P, Sheng L, Wang G, Wang H, Huang X, Yan X, Yang X, Pei R. Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma. Mol Clin Oncol 2014;2:203-6. [PMID: 24649333 DOI: 10.3892/mco.2014.239] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
76 Ye F, Che Y, McMillen E, Gorski J, Brodman D, Saw D, Jiang B, Zhang DY. The effect of Scutellaria baicalensis on the signaling network in hepatocellular carcinoma cells. Nutr Cancer. 2009;61:530-537. [PMID: 19838925 DOI: 10.1080/01635580902803719] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
77 Wiedmann M, Zeh J, Schoppmeyer K, Moebius C, Niederhagen M, Wittekind C, Mossner J, Caca K. Bendamustine--a new approach to the treatment of advanced hepatocellular carcinoma? J Chemother 2008;20:112-8. [PMID: 18343753 DOI: 10.1179/joc.2008.20.1.112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg. 2006;202:155-168. [PMID: 16377509 DOI: 10.1016/j.jamcollsurg.2005.06.263] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
79 Arellano RS. What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. Curr Oncol Rep 2020;22:105. [PMID: 32725433 DOI: 10.1007/s11912-020-00967-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 He C, Zhang Y, Cai Z, Lin X. The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. Cancer Manag Res 2019;11:1391-400. [PMID: 30863150 DOI: 10.2147/CMAR.S190545] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
81 Liu X, Cheng Q, Geng W, Ling C, Liu Y, Ng KT, Yam JW, Guan X, Lo C, Man K. Enhancement of cisplatin-based TACE by a hemoglobin-based oxygen carrier in an orthotopic rat HCC model. Artificial Cells, Nanomedicine, and Biotechnology 2013;42:229-36. [DOI: 10.3109/21691401.2013.808647] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
82 Aboian MS, Yu JF, Gautam A, Sze CH, Yang JK, Chan J, Lillaney PV, Jordan CD, Oh HJ, Wilson DM, Patel AS, Wilson MW, Hetts SW. In vitro clearance of doxorubicin with a DNA-based filtration device designed for intravascular use with intra-arterial chemotherapy. Biomed Microdevices 2016;18:98. [PMID: 27778226 DOI: 10.1007/s10544-016-0124-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
83 Bala MM, Riemsma RP, Wolff R, Kleijnen J, Bala MM. Cryotherapy for liver metastases. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd009058] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
84 Cohen GS, Black M. Multidisciplinary management of hepatocellular carcinoma: a model for therapy. J Multidiscip Healthc. 2013;6:189-195. [PMID: 23690690 DOI: 10.2147/jmdh.s41206] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
85 Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol. 2005;31:331-347. [PMID: 15837037 DOI: 10.1016/j.ejso.2004.10.011] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
86 Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013; 19(21): 3207-3216 [PMID: 23745022 DOI: 10.3748/wjg.v19.i21.3207] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
87 Blanc JF, Debaillon-Vesque A, Roth G, Barbare JC, Baumann AS, Boige V, Boudjema K, Bouattour M, Crehange G, Dauvois B, Decaens T, Dewaele F, Farges O, Guiu B, Hollebecque A, Merle P, Selves J, Aparicio T, Ruiz I, Bouché O; Thésaurus National de Cancérologie Digestive (TNCD)., Société Nationale Française de Gastroentérologie (SNFGE)., Fédération Francophone de Cancérologie Digestive (FFCD)., Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Société Française de Chirurgie Digestive (SFCD)., Société Française d’Endoscopie Digestive (SFED)., Société Française de Radiothérapie Oncologique (SFRO)., Association Française pour l’Etude du Foie (AFEF). Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). Clin Res Hepatol Gastroenterol 2021;45:101590. [PMID: 33780876 DOI: 10.1016/j.clinre.2020.101590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Bala MM, Riemsma RP, Wolff R, Pedziwiatr M, Mitus JW, Storman D, Swierz MJ, Kleijnen J. Cryotherapy for liver metastases. Cochrane Database Syst Rev 2019;7:CD009058. [PMID: 31291464 DOI: 10.1002/14651858.CD009058.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Mortensen HR, Villadsen GE, Worm ES, Weber B. Survival and morbidity following stereotactic radiotherapy of hepatocellular carcinoma: a ten-year, single institution experience. Scand J Gastroenterol 2021;56:259-65. [PMID: 33430663 DOI: 10.1080/00365521.2020.1869822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann Surg Oncol. 2014;21:3069-3076. [PMID: 24728740 DOI: 10.1245/s10434-014-3704-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
91 El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, McGlynn KA. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158-166. [PMID: 16290309 DOI: 10.1016/j.jhep.2005.10.002] [Cited by in Crossref: 168] [Cited by in F6Publishing: 150] [Article Influence: 9.9] [Reference Citation Analysis]
92 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33:33-40. [PMID: 21931992 DOI: 10.1007/s13277-011-0237-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
93 Perera S, Kelly D, O'Kane GM. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Curr Oncol 2020;27:S165-72. [PMID: 33343210 DOI: 10.3747/co.27.7159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
94 Schwind N, Ray CE Jr, Gaba RC. Hepatoma Rupture following Drug-Eluting Bead Chemoembolization. Semin Intervent Radiol 2015;32:225-30. [PMID: 26038629 DOI: 10.1055/s-0035-1549845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
95 Montasser A, Beaufrère A, Cauchy F, Bouattour M, Soubrane O, Albuquerque M, Paradis V. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology 2021;79:36-46. [PMID: 33326644 DOI: 10.1111/his.14317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Rogério CPA, Daniele A, Betty G, Carla M, Monica V, Michele H, Deborah T, Mario K, Otavio G, Paula P. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Annals of Hepatology 2011;10:21-7. [DOI: 10.1016/s1665-2681(19)31582-0] [Cited by in Crossref: 53] [Article Influence: 4.8] [Reference Citation Analysis]
97 Abou-Alfa GK. TACE and sorafenib: a good marriage? J Clin Oncol. 2011;29:3949-3952. [PMID: 21911718 DOI: 10.1200/jco.2011.37.9651] [Cited by in Crossref: 43] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
98 Shen PC, Chang WC, Lo CH, Yang JF, Lee MS, Dai YH, Lin CS, Fan CY, Huang WY. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2019;105:307-18. [PMID: 31175903 DOI: 10.1016/j.ijrobp.2019.05.066] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
99 Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH; Asian Oncology Summit. Management of hepatocellular carcinoma in Asia: Consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1111-1118. [PMID: 19880065 DOI: 10.1016/s1470-2045(09)70241-4] [Cited by in Crossref: 268] [Cited by in F6Publishing: 137] [Article Influence: 20.6] [Reference Citation Analysis]
100 Liu Y, Ren Y, Ge S, Xiong B, Zhou G, Feng G, Song S, Zheng C. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome and Risk Signature Analysis. Front Oncol 2021;11:662408. [PMID: 34155478 DOI: 10.3389/fonc.2021.662408] [Reference Citation Analysis]
101 Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R. A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization. American Journal of Transplantation 2009;9:1920-8. [DOI: 10.1111/j.1600-6143.2009.02695.x] [Cited by in Crossref: 361] [Cited by in F6Publishing: 315] [Article Influence: 27.8] [Reference Citation Analysis]
102 Gao S, Yang RJ, Dong JH. Hepatocellular carcinoma with blood supply from parasitized omental artery: angiographic appearance and chemoembolization. Chin J Cancer Res 2012;24:207-12. [PMID: 23359452 DOI: 10.1007/s11670-012-0207-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
103 Alves A, Mamede A, Alves M, Oliveira P, Rocha S, Botelho M, Maia C. Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment? CCDT 2018;19:26-40. [DOI: 10.2174/1568009618666180430144441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
104 Hetta WM, Shebria N. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres. The Egyptian Journal of Radiology and Nuclear Medicine 2014;45:761-9. [DOI: 10.1016/j.ejrnm.2014.04.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Skowasch M, Schneider J, Otto G, Weinmann A, Woerns MA, Dueber C, Pitton MB. Midterm follow-up after DC-BEAD™-TACE of hepatocellular carcinoma (HCC). Eur J Radiol. 2012;81:3857-3861. [PMID: 22840383 DOI: 10.1016/j.ejrad.2012.07.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
106 Demeria D, Birchall I, Bain VG. Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy. Can J Gastroenterol 2007;21:517-8. [PMID: 17703252 DOI: 10.1155/2007/128792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
107 Lee IJ, Seong J. Radiosensitizers in Hepatocellular Carcinoma. Seminars in Radiation Oncology 2011;21:303-11. [DOI: 10.1016/j.semradonc.2011.05.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
108 Pacella CM, Francica G, Di Lascio FM, Arienti V, Antico E, Caspani B, Magnolfi F, Megna AS, Pretolani S, Regine R. Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. J Clin Oncol. 2009;27:2615-2621. [PMID: 19332729 DOI: 10.1200/jco.2008.19.0082] [Cited by in Crossref: 86] [Cited by in F6Publishing: 22] [Article Influence: 6.6] [Reference Citation Analysis]
109 Li F, Wang F, Li J, Yang XS. Nexavar in combination with interventional therapy for hepatocellular carcinoma: a report of 20 cases. Shijie Huaren Xiaohua Zazhi 2010; 18(5): 517-520 [DOI: 10.11569/wcjd.v18.i5.517] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006;25:3848-3856. [PMID: 16799626 DOI: 10.1038/sj.onc.1209548] [Cited by in Crossref: 109] [Cited by in F6Publishing: 100] [Article Influence: 6.8] [Reference Citation Analysis]
111 Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:920-925. [PMID: 24224722 DOI: 10.1111/jgh.12439] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 7.6] [Reference Citation Analysis]
112 Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen Hepatology. 2004;40:1361-1369. [PMID: 15565568 DOI: 10.1002/hep.20474] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
113 Saito M, Seo Y, Yano Y, Momose K, Hirano H, Yoshida M, Azuma T. Reduction in non-protein respiratory quotient is related to overall survival after hepatocellular carcinoma treatment. PLoS One 2013;8:e55441. [PMID: 23520445 DOI: 10.1371/journal.pone.0055441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
115 Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-Improvement Guidelines for Hepatic Transarterial Chemoembolization. Cardiovasc Intervent Radiol 2012;35:765-74. [DOI: 10.1007/s00270-012-0423-z] [Reference Citation Analysis]
116 San Miguel C, Muffak K, Triguero J, Becerra A, Villegas T, Nogueras F, Expósito M, Fundora Y. Role of Transarterial Chemoembolization to Downstage Hepatocellular Carcinoma Within the Milan Criteria. Transplantation Proceedings 2015;47:2631-3. [DOI: 10.1016/j.transproceed.2015.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
117 Andersen KJ, Grønbæk H, Villadsen GE, Knudsen AR, Ott P, Vildstrup H, Nielsen DT, Bharadwaz A. Chemoembolization of intermediate stage hepatocellular carcinomas: Results from a Nordic tertiary liver cancer center. Indian J Gastroenterol 2014;33:322-9. [DOI: 10.1007/s12664-013-0428-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
118 Zhang Y, Huang G, Wang Y, Liang L, Peng B, Fan W, Yang J, Huang Y, Yao W, Li J. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience. Oncologist 2016;21:1442-9. [PMID: 27486202 DOI: 10.1634/theoncologist.2016-0094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
119 Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2017;15:1791-9. [PMID: 28579181 DOI: 10.1016/j.cgh.2017.05.036] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
120 Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, Park SY, Yang JM. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50:445-454. [PMID: 25027973 DOI: 10.1007/s00535-014-0978-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
121 Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. The Lancet Oncology 2004;5:409-18. [DOI: 10.1016/s1470-2045(04)01508-6] [Cited by in Crossref: 117] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
122 Bova V, Miraglia R, Maruzzelli L, Vizzini GB, Luca A. Predictive factors of downstaging of hepatocellular carcinoma beyond the Milan criteria treated with intra-arterial therapies. Cardiovasc Intervent Radiol 2013;36:433-9. [PMID: 22864644 DOI: 10.1007/s00270-012-0458-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
123 Donadon M, Fontana A, Procopio F, Del Fabbro D, Cimino M, Viganò L, Palmisano A, Torzilli G. Dissecting the multinodular hepatocellular carcinoma subset: is there a survival benefit after hepatectomy? Updates Surg 2019;71:57-66. [DOI: 10.1007/s13304-019-00626-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
124 Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer 2021;21:1157. [PMID: 34715816 DOI: 10.1186/s12885-021-08904-3] [Reference Citation Analysis]
125 Abou-Alfa GK. Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning? Oncologist. 2009;14:92-94. [PMID: 19144679 DOI: 10.1634/theoncologist.2008-0294] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
126 Megìas Vericat JE, Garcia Marcos R, Lopez Briz E, Gòmez Munoz F, Ramos Ruiz J, Martinez Rodrigo JJ, Poveda Andrés JL. Trans-arterial Chemoembolization with Doxorubicin-eluting Particles versus Conventional Trans-arterial Chemoembolization in Unresectable Hepatocellular Carcinoma: a Study of Effectiveness, Safety and Costs. Radiologia. 2015;57:496-504. [PMID: 25857250 DOI: 10.1016/j.rx.2015.01.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
127 Spreafico C, Cascella T, Facciorusso A, Sposito C, Rodolfo L, Morosi C, Civelli EM, Vaiani M, Bhoori S, Pellegrinelli A. Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile. Cardiovasc Intervent Radiol. 2015;38:129-134. [PMID: 24870698 DOI: 10.1007/s00270-014-0907-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
128 Hesketh RL, Zhu AX, Oklu R. Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma? Diagn Interv Radiol 2015;21:78-84. [PMID: 25430530 DOI: 10.5152/dir.2014.14237] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
129 Schwartz M, Lopez P. Waiting List Treatment of Hepatocellular Carcinoma: When Do We Need Level 1 Evidence? Am J Transplant 2006;6:2531-2. [DOI: 10.1111/j.1600-6143.2006.01572.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
130 Zou X, Fan W, Xue M, Li J. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Manag Res 2021;13:4013-29. [PMID: 34040442 DOI: 10.2147/CMAR.S304591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Wu L, Xu P, Rao S, Yang L, Chen C, Liu H, Fu C, Zeng M. ADCtotal ratio and D ratio derived from intravoxel incoherent motion early after TACE are independent predictors for survival in hepatocellular carcinoma. J Magn Reson Imaging 2017;46:820-30. [PMID: 28276105 DOI: 10.1002/jmri.25617] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
132 Zhang Y, Jiang L, Wen J, Liu D, Huang G, Wang Y, Fan W, Li J. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology 2018;29:1654-61. [DOI: 10.1016/j.jvir.2018.07.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
133 Yoshimatsu R, Yamagami T, Ishikawa M, Kajiwara K, Aikata H, Chayama K, Awai K. Change in Imaging Findings on Angiography-Assisted CT During Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2016;39:865-874. [PMID: 26711803 DOI: 10.1007/s00270-015-1279-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
134 Mohr I, Vogeler M, Pfeiffenberger J, Sprengel SD, Klauss M, Radeleff B, Teufel A, Chang D, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-021-03900-3] [Reference Citation Analysis]
135 Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E;  ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238-iv255. [PMID: 30285213 DOI: 10.1093/annonc/mdy308] [Cited by in Crossref: 230] [Cited by in F6Publishing: 204] [Article Influence: 76.7] [Reference Citation Analysis]
136 Heng-jun G, Yao-jun Z, Min-shan C, Mei-xian C, Jun-ting H, Li X, Lau WY. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. Liver Int 2014;34:612-20. [DOI: 10.1111/liv.12307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
137 Ueda T, Murata S, Yasui D, Mine T, Kumita S. Comparison of the antitumor efficacy of transcatheter arterial chemoembolization with a miriplatin-iodized oil suspension and a cisplatin-iodized oil suspension for hepatocellular carcinoma: Miriplatin versus cisplatin suspensions. Hepatol Res 2013. [DOI: 10.1111/hepr.12212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
138 Yeh ML, Huang CI, Huang CF, Hsieh MY, Huang JF, Dai CY, Lin ZY, Chen SC, Yu ML, Chuang WL. Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. Kaohsiung J Med Sci 2015;31:77-82. [PMID: 25645985 DOI: 10.1016/j.kjms.2014.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
139 O’Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J Gastroenterol 2018; 24(39): 4436-4447 [PMID: 30357021 DOI: 10.3748/wjg.v24.i39.4436] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
140 Xia HB, Wang HJ, Fu LQ, Wang SB, Li L, Ru GQ, He XL, Tong XM, Mou XZ, Huang DS. Decreased CRHBP expression is predictive of poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2018;16:3681-9. [PMID: 30127978 DOI: 10.3892/ol.2018.9073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
141 Takahashi A, Yamamoto Y, Yasunaga M, Koga Y, Kuroda J, Takigahira M, Harada M, Saito H, Hayashi T, Kato Y, Kinoshita T, Ohkohchi N, Hyodo I, Matsumura Y. NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci 2013;104:920-5. [PMID: 23495762 DOI: 10.1111/cas.12153] [Cited by in Crossref: 82] [Cited by in F6Publishing: 65] [Article Influence: 9.1] [Reference Citation Analysis]
142 Guo Z, Zhong Y, Hu B, Jiang JH, Li LQ, Xiang BD. Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma within Milan criteria: A propensity score matching analysis. Medicine (Baltimore) 2017;96:e8933. [PMID: 29390426 DOI: 10.1097/MD.0000000000008933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Jiang J, Hu H, Liu R, Wang JH, Long XR, Fan J, Yan ZP. Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e7390. [PMID: 28796032 DOI: 10.1097/MD.0000000000007390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
144 Lee YH, Hsu CY, Huang YH, Hsia CY, Chiou YY, Su CW, Lin HC, Huo TI. Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact. J Clin Gastroenterol 2014;48:734-41. [PMID: 24100755 DOI: 10.1097/MCG.0b013e3182a8a254] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
145 Kimhofer T, Fye H, Taylor-Robinson S, Thursz M, Holmes E. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br J Cancer. 2015;112:1141-1156. [PMID: 25826224 DOI: 10.1038/bjc.2015.38] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 10.4] [Reference Citation Analysis]
146 Cho Y, Lee JH, Lee DH, Cho EJ, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget 2017;8:47555-64. [PMID: 28548930 DOI: 10.18632/oncotarget.17733] [Reference Citation Analysis]
147 Mcnally ME, Martinez A, Khabiri H, Guy G, Michaels AJ, Hanje J, Kirkpatrick R, Bloomston M, Schmidt CR. Inflammatory Markers are Associated with Outcome in Patients with Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Ann Surg Oncol 2013;20:923-8. [DOI: 10.1245/s10434-012-2639-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
148 Lee S, Kang JH, Kim DY, Ahn SH, Park JY, Kim BK, Kim SU, Han KH. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. Hepatol Int. 2017;11:292-299. [PMID: 28324324 DOI: 10.1007/s12072-017-9792-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
149 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 110] [Article Influence: 16.9] [Reference Citation Analysis]
150 Kinney TB. Editorial Comment: A Cautionary Experience With Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma. AJR Am J Roentgenol 2021;217:944. [PMID: 33355490 DOI: 10.2214/AJR.20.25284] [Reference Citation Analysis]
151 Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization: Drop-Out Rates for HCC. Liver Transpl 2004;10:449-55. [DOI: 10.1002/lt.20099] [Cited by in Crossref: 168] [Cited by in F6Publishing: 152] [Article Influence: 9.3] [Reference Citation Analysis]
152 Nowak AK, Stockler MR, Chow PKH, Findlay M. Use of tamoxifen in advanced-stage hepatocellular carcinoma: A systematic review. Cancer 2005;103:1408-14. [DOI: 10.1002/cncr.20963] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
153 Han Z, Yang, Trivett A, Oppenheim JJ. Therapeutic vaccine to cure large mouse hepatocellular carcinomas. Oncotarget 2017;8:52061-71. [PMID: 28881713 DOI: 10.18632/oncotarget.19367] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
154 Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258:627-634. [PMID: 21273524 DOI: 10.1148/radiol.10101058] [Cited by in Crossref: 165] [Cited by in F6Publishing: 166] [Article Influence: 15.0] [Reference Citation Analysis]
155 Liu W, Xiu N, Zhao J, Zhao L. Enhanced therapeutic effect of transcatheter arterial chemoembolization combined with radioactive I-125 seed implantation on liver cancer. Oncol Lett 2020;20:2493-8. [PMID: 32782568 DOI: 10.3892/ol.2020.11765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631-1639. [PMID: 23547075 DOI: 10.1200/jco.2012.44.1659] [Cited by in Crossref: 445] [Cited by in F6Publishing: 215] [Article Influence: 49.4] [Reference Citation Analysis]
157 Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology. 2011;53:160-170. [PMID: 20979057 DOI: 10.1002/hep.24000] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.8] [Reference Citation Analysis]
158 Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013; 19(43): 7515-7530 [PMID: 24282343 DOI: 10.3748/wjg.v19.i43.7515] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 57] [Article Influence: 7.7] [Reference Citation Analysis]
159 Gao F, Jing P, Liu J, Lu Y, Zhang P, Han W, Liu G, Ru N, Cui G, Sun C, Che Y, Zhang H, Hu Q, Wang HY, Wu Y, Guan C, Fu Q, Ma Z, Yu B. Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy. J Hepatocell Carcinoma 2015;2:57-68. [PMID: 27508195 DOI: 10.2147/JHC.S80756] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016; 22(1): 232-252 [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
161 Iwazawa J, Ohue S, Hashimoto N, Mitani T. Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin. Cancer Manag Res. 2012;4:113-119. [PMID: 22570565 DOI: 10.2147/cmar.s30431] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
162 Moya Herráiz A, Torres-Quevedo R, Mir Pallardó J. [Liver transplant in patients with hepatocellular carcinoma]. Cir Esp 2008;84:117-24. [PMID: 18783669 DOI: 10.1016/s0009-739x(08)72152-3] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
163 Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother. 2005;28:496-504. [PMID: 16113606 DOI: 10.1097/01.cji.0000171291.72039.e2] [Cited by in Crossref: 123] [Cited by in F6Publishing: 113] [Article Influence: 7.2] [Reference Citation Analysis]
164 Chevallier P, Baudin G, Anty R, Guibal A, Chassang M, Avril L, Tran A. Treatment of hepatocellular carcinomas by thermal ablation and hepatic transarterial chemoembolization. Diagnostic and Interventional Imaging 2015;96:637-46. [DOI: 10.1016/j.diii.2015.04.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
165 González HD, Figueras J. Surgical treatment for hepatocellular carcinoma in cirrhotic patients. Guide to the selection and decision-making process in a context of multimodal strategy. Clin Transl Oncol 2009;11:20-7. [DOI: 10.1007/s12094-009-0306-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
166 Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, Wawrzynek W, Stroszczynski C. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit. 2011;17:CR189-CR195. [PMID: 21455104 DOI: 10.12659/msm.881714] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
167 Sato M, Morimoto K, Kajihara S, Tateishi R, Shiina S, Koike K, Yatomi Y. Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. Sci Rep. 2019;9:7704. [PMID: 31147560 DOI: 10.1038/s41598-019-44022-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
168 Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24:2565-2570. [PMID: 23857958 DOI: 10.1093/annonc/mdt247] [Cited by in Crossref: 164] [Cited by in F6Publishing: 145] [Article Influence: 18.2] [Reference Citation Analysis]
169 Wang G, Liu Y, Zhou SF, Qiu P, Xu L, Wen P, Wen J, Xiao X. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatol Int. 2016;10:501-510. [PMID: 26856326 DOI: 10.1007/s12072-015-9700-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
170 Xing M, Sakaria S, Dhanasekaran R, Parekh S, Spivey J, Knechtle SJ, Zhang D, Kim HS. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2017;40:410-420. [PMID: 27900445 DOI: 10.1007/s00270-016-1505-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
171 Palagyi A, Neveling K, Plinninger U, Ziesch A, Targosz BS, Denk GU, Ochs S, Rizzani A, Meier D, Thasler WE, Hanenberg H, De Toni EN, Bassermann F, Schäfer C, Göke B, Schindler D, Gallmeier E. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer 2010;9:127. [PMID: 20509860 DOI: 10.1186/1476-4598-9-127] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
172 Guo W, Chen S, Wu Z, Zhuang W, Yang J. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Technol Cancer Res Treat 2020;19:1533033820965587. [PMID: 33089769 DOI: 10.1177/1533033820965587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Takamoto T, Makuuchi M. Precision surgery for primary liver cancer. Cancer Biol Med 2019;16:475-85. [PMID: 31565478 DOI: 10.20892/j.issn.2095-3941.2019.0194] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
174 Son SH, Jang HS, Sung SY, Kang HJ, Lee S, Kay CS. Identifying the optimal criteria of radiotherapeutic parameters for patients with unresectable locally advanced hepatocellular carcinoma. Oncotarget 2015;6:42372-9. [PMID: 26510905 DOI: 10.18632/oncotarget.5713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
175 Vilgrain V, Sibert A, Zappa M, Belghiti J. Sequential arterial and portal vein embolization in patients with cirrhosis and hepatocellular carcinoma: the hospital beaujon experience. Semin Intervent Radiol 2008;25:155-61. [PMID: 21326556 DOI: 10.1055/s-2008-1076689] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
176 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic. J Gastroenterol Hepatol 2019;34:1066-73. [PMID: 30549320 DOI: 10.1111/jgh.14564] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
177 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
178 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
179 Cheung TT, Kwok PC, Chan S, Cheung CC, Lee AS, Lee V, Cheng HC, Chia NH, Chong CCN, Lai TW, Law ALY, Luk MY, Tong CC, Yau TCC. Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer 2018;7:40-54. [PMID: 29662832 DOI: 10.1159/000485984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
180 Luvai A, Mbagaya W, Narayanan D, Degg T, Toogood G, Wyatt JI, Swinson D, Hall CJ, Barth JH. Hepatocellular carcinoma in variegate porphyria: a case report and literature review. Ann Clin Biochem 2015;52:407-12. [PMID: 25301776 DOI: 10.1177/0004563214557568] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
181 Zhou ZG, Chen JB, Zhang RX, Ye L, Wang JC, Pan YX, Wang XH, Li WX, Zhang YJ, Xu L, Chen MS. Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients. Cancer Commun (Lond) 2020;40:355-69. [PMID: 32609436 DOI: 10.1002/cac2.12069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373. [PMID: 24488546 DOI: 10.1007/s11912-013-0373-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
183 Nasser F, Cavalcante RN, Galastri FL, de Rezende MB, Felga GG, Travassos FB, De Fina B, Affonso BB. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program. J Vasc Interv Radiol. 2014;25:1012-1017. [PMID: 24704346 DOI: 10.1016/j.jvir.2014.02.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
184 Zhao C, Feng Q, Dou Z, Yuan W, Sui C, Zhang X, Xia G, Sun H, Ma J. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin. PLoS One 2013;8:e73860. [PMID: 24040096 DOI: 10.1371/journal.pone.0073860] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
185 Cárdenes HR, Lasley F. Primary Liver Cancer. In: Lo SS, Teh BS, Lu JJ, Schefter TE, editors. Stereotactic Body Radiation Therapy. Berlin: Springer Berlin Heidelberg; 2012. pp. 163-82. [DOI: 10.1007/174_2012_548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
186 Cheng AL, Amarapurkar D, Chao Y, Chen P, Geschwind J, Goh KL, Han K, Kudo M, Lee HC, Lee R, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan C, Tanwandee T, Teng G, Park J. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. [DOI: 10.1111/liv.12314] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
187 Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, Zhang YQ. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:1437-1445. [PMID: 19408012 DOI: 10.1007/s00432-009-0588-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 5.6] [Reference Citation Analysis]
188 Roessler S, Budhu A, Wang XW. Future of molecular profiling of human hepatocellular carcinoma. Future Oncol. 2007;3:429-439. [PMID: 17661718 DOI: 10.2217/14796694.3.4.429] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
189 Gu K, Lai S, Ma N, Zhao J, Ren Z, Wang J, Liu J, Jiang G. Hepatic Regeneration after Sublethal Partial Liver Irradiation in Cirrhotic Rats. JRR 2011;52:582-91. [DOI: 10.1269/jrr.11002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
190 Boucher E, Forner A, Reig M, Bruix J. New drugs for the treatment of hepatocellular carcinoma. Liver Int 2009;29 Suppl 1:148-58. [PMID: 19207980 DOI: 10.1111/j.1478-3231.2008.01929.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
191 Sun X, Jiang H, Jiang X, Tan H, Meng Q, Sun B, Xu R, Krissansen GW. Antisense hypoxia-inducible factor-1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats. Hum Gene Ther. 2009;20:314-324. [PMID: 19327024 DOI: 10.1089/hum.2008.164] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
192 Mabed M, Esmaeel M, El-khodary T, Awad M, Amer T. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. European Journal of Cancer Care 2009;18:492-9. [DOI: 10.1111/j.1365-2354.2008.00984.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
193 King MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. European Journal of Radiology 2020;133:109351. [DOI: 10.1016/j.ejrad.2020.109351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
194 Sen G, Rai R, Manas DM. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma ( Br J Surg 2003; 90: 325-331). British Journal of Surgery 2003;90:1022-1022. [DOI: 10.1002/bjs.4361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
195 Díaz Sánchez A, Núñez Martínez O, Prieto Martín M, Beceiro Pedreño I, Calleja Kempin J, Santos Castro L, Muro de la Fuente A, Clemente Ricote G, Matilla Peña A. [Prognostic factors in patients with non-active treatment of hepatocellular carcinoma]. Gastroenterol Hepatol 2007;30:441-8. [PMID: 17949609 DOI: 10.1157/13110488] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
196 Isaac EI, Hall J, Dault JB, Elbich J, Mcghee A, Fields EC. Transarterial Chemoembolization with LC Bead LUMI followed by Stereotactic Body Radiation Therapy in Treatment of Hepatocellular Carcinoma. Advances in Radiation Oncology 2022;7:100830. [DOI: 10.1016/j.adro.2021.100830] [Reference Citation Analysis]
197 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
198 Tada M, Yokosuka O, Fukai K, Chiba T, Imazeki F, Tokuhisa T, Saisho H. Hypermethylation of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma. J Hepatol. 2005;42:511-519. [PMID: 15763338 DOI: 10.1016/j.jhep.2004.11.024] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
199 Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013;119:1042-1049. [PMID: 23132335 DOI: 10.1002/cncr.27859] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
200 Danno K, Nakamura T, Okoso N, Nakamura N, Iguchi K, Iwadate Y, Kenmotsu T, Ikegawa M, Uemoto S, Yoshikawa K. Cracking pattern of tissue slices induced by external extension provides useful diagnostic information. Sci Rep 2018;8:12167. [PMID: 30111854 DOI: 10.1038/s41598-018-30662-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
201 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
202 Zhai XF, Chen Z, Li B, Shen F, Fan J, Zhou WP, Yang YK, Xu J, Qin X, Li LQ. Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial. J Integr Med. 2013;11:90-100. [PMID: 23506690 DOI: 10.3736/jintegrmed2013021] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 6.7] [Reference Citation Analysis]
203 Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73. [DOI: 10.1002/hep.23725] [Cited by in Crossref: 323] [Cited by in F6Publishing: 320] [Article Influence: 26.9] [Reference Citation Analysis]
204 Bouvier A, Ozenne V, Aubé C, Boursier J, Vullierme MP, Thouveny F, Farges O, Vilgrain V. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 2011;21:1719-26. [PMID: 21479978 DOI: 10.1007/s00330-011-2118-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
205 Knight SR, Friend PJ, Morris PJ. Role of transplantation in the management of hepatic malignancy. British Journal of Surgery 2007;94:1319-30. [DOI: 10.1002/bjs.5968] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
206 Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019;16:617-630. [PMID: 31371809 DOI: 10.1038/s41575-019-0179-x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 19.0] [Reference Citation Analysis]
207 Moriguchi M, Takayama T, Nakamura M, Aramaki O, Higaki T, Nakayama H, Ohkubo T, Fujii M. Phase I/II study of a fine-powder formulation of cisplatin for transcatheter arterial chemoembolization in hepatocellular carcinoma. Hepatology Research 2010;40:369-75. [DOI: 10.1111/j.1872-034x.2009.00606.x] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
208 Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, Navarria P, Fogliata A, Tomatis S, D'Agostino G, Iftode C, Mancosu P, Ceriani R, Torzilli G. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015;141:1301-1309. [PMID: 25644863 DOI: 10.1007/s00432-015-1929-y] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 13.3] [Reference Citation Analysis]
209 Terzi E, Piscaglia F, Forlani L, Mosconi C, Renzulli M, Bolondi L, Golfieri R; BLOG-Bologna Liver Oncology Group, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. TACE performed in patients with a single nodule of hepatocellular carcinoma. BMC Cancer 2014;14:601. [PMID: 25139639 DOI: 10.1186/1471-2407-14-601] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
210 Eichler K, Zangos S, Mack MG, Hammerstingl R, Gruber-Rouh T, Gallus C, Vogl TJ. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). Int J Oncol. 2012;41:1213-1220. [PMID: 22842404 DOI: 10.3892/ijo.2012.1572] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
211 Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358-380. [PMID: 28130846 DOI: 10.1002/hep.29086] [Cited by in Crossref: 1290] [Cited by in F6Publishing: 1210] [Article Influence: 322.5] [Reference Citation Analysis]
212 Wörns MA, Galle PR. Sorafenib for the treatment of hepatocellular carcinoma. Hepat Oncol 2014;1:189-204. [PMID: 30190954 DOI: 10.2217/hep.13.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
213 Peng H, Xue R, Ju Z, Qiu J, Wang J, Yan W, Gan X, Tian Y, Shen H, Wang X, Wang X, Ni X, Yu Y, Lu L. Cancer-associated fibroblasts enhance the chemoresistance of CD73+ hepatocellular carcinoma cancer cells via HGF-Met-ERK1/2 pathway. Ann Transl Med 2020;8:856. [PMID: 32793700 DOI: 10.21037/atm-20-1038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
214 Zigmond E, Ben Ya'acov A, Lee H, Lichtenstein Y, Shalev Z, Smith Y, Zolotarov L, Ziv E, Kalman R, Le HV, Lu H, Silverman RB, Ilan Y. Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase. ACS Med Chem Lett 2015;6:840-4. [PMID: 26288681 DOI: 10.1021/acsmedchemlett.5b00153] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
215 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 94] [Article Influence: 2.3] [Reference Citation Analysis]
216 Shaghaghi M, AliyariG Hasabeh M, Ameli S, Ghadimi M, Hazhirkarzar B, Rezvani Habibabadi R, Tang H, Khoshpouri P, Wu Q, Pandey A, Pandey P, Baghdadi A, Kamel IR. Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC. Eur J Radiol 2020;133:109389. [PMID: 33166831 DOI: 10.1016/j.ejrad.2020.109389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, Bolondi L. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2010;22:391-398. [PMID: 19940784 DOI: 10.1097/meg.0b013e328333df23] [Cited by in Crossref: 44] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
218 Zhang L, Yin X, Gan YH, Zhang BH, Zhang JB, Chen Y, Xie XY, Ge NL, Wang YH, Ye SL. Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria. BMC Gastroenterol. 2014;14:11. [PMID: 24410841 DOI: 10.1186/1471-230x-14-11] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
219 Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100498] [Reference Citation Analysis]
220 Huo TI, Wu JC, Huang YH, Chiang JH, Lee PC, Chang FY, Lee SD. Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Aliment Pharmacol Ther. 2004;19:999-1007. [PMID: 15113367 DOI: 10.1111/j.1365-2036.2004.01936.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
221 Wen X, Jiang X, Li R, Zhang J, Yang P, Shen B. Novel X-Ray Imaging Technology Allows Substantial Patient Radiation Reduction without Image Quality Impairment in Repetitive Transarterial Chemoembolization for Hepatocellular Carcinoma. Academic Radiology 2015;22:1361-7. [DOI: 10.1016/j.acra.2015.07.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
222 Pouponneau P, Leroux J, Martel S. Magnetic nanoparticles encapsulated into biodegradable microparticles steered with an upgraded magnetic resonance imaging system for tumor chemoembolization. Biomaterials 2009;30:6327-32. [DOI: 10.1016/j.biomaterials.2009.08.005] [Cited by in Crossref: 106] [Cited by in F6Publishing: 66] [Article Influence: 8.2] [Reference Citation Analysis]
223 Galanakis N, Kehagias E, Matthaiou N, Samonakis D, Tsetis D. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. Hepat Oncol 2018;5:HEP07. [PMID: 31293775 DOI: 10.2217/hep-2018-0001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
224 Sarkar D. AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res 2013;120:193-221. [PMID: 23889992 DOI: 10.1016/B978-0-12-401676-7.00007-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
225 Nakano MM, Yamamoto A, Nishida N, Hamuro M, Hamamoto S, Jogo A, Sohgawa E, Kageyama K, Minami T, Miki Y. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). Jpn J Radiol 2019;37:543-8. [DOI: 10.1007/s11604-019-00840-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
226 Inokawa Y, Inaoka K, Sonohara F, Hayashi M, Kanda M, Nomoto S. Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncol Lett 2016;12:3662-8. [PMID: 27900050 DOI: 10.3892/ol.2016.5141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
227 Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012;56:1330-1335. [PMID: 22314428 DOI: 10.1016/j.jhep.2012.01.008] [Cited by in Crossref: 284] [Cited by in F6Publishing: 263] [Article Influence: 28.4] [Reference Citation Analysis]
228 Robertson CL, Srivastava J, Rajasekaran D, Gredler R, Akiel MA, Jariwala N, Siddiq A, Emdad L, Fisher PB, Sarkar D. The role of AEG-1 in the development of liver cancer. Hepat Oncol 2015;2:303-12. [PMID: 26798451 DOI: 10.2217/hep.15.10] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
229 Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol. 2018;6:69-78. [PMID: 29607307 DOI: 10.14218/jcth.2017.00031] [Cited by in Crossref: 97] [Cited by in F6Publishing: 76] [Article Influence: 19.4] [Reference Citation Analysis]
230 Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117-2127. [PMID: 21664811 DOI: 10.1016/j.ejca.2011.05.007] [Cited by in Crossref: 304] [Cited by in F6Publishing: 328] [Article Influence: 27.6] [Reference Citation Analysis]
231 Pasic I, Wong KM, Lee JJ, Espin-Garcia O, Brhane Y, Cheng D, Chen Z, Patel D, Brown C, Bucur R, Reisman D, Knox JJ, Xu W, Hung RJ, Liu G, Cleary SP. Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma. Mol Carcinog 2018;57:106-13. [PMID: 28892201 DOI: 10.1002/mc.22736] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
232 Kawabe N, Hashimoto S, Nakano T, Nakaoka K, Fukui A, Yoshioka K. Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. JGH Open 2021;5:705-11. [PMID: 34124389 DOI: 10.1002/jgh3.12573] [Reference Citation Analysis]
233 Harlan LC, Parsons HM, Wiggins CL, Stevens JL, Patt YZ. Treatment of hepatocellular carcinoma in the community: disparities in standard therapy. Liver Cancer. 2015;4:70-83. [PMID: 26020030 DOI: 10.1159/000367729] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
234 Siramolpiwat S, Punjachaipornpon T, Pornthisarn B, Vilaichone RK, Chonprasertsuk S, Tangaroonsanti A, Bhanthumkomol P, Phumyen A, Yasiri A, Kaewmanee M. N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization. Dig Dis Sci 2019;64:3337-45. [PMID: 31073737 DOI: 10.1007/s10620-019-05652-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
235 Chen D, Shen M, Cao Y, Bo B, Chen Z, Shu Y, Li G. Electrochemical identification of hepatocellular carcinoma based on the assay of human cervical cancer oncoprotein-1 in serum. Electrochemistry Communications 2013;27:38-41. [DOI: 10.1016/j.elecom.2012.10.042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
236 Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol. 2009;193:1044-1052. [PMID: 19770328 DOI: 10.2214/ajr.08.1461] [Cited by in Crossref: 137] [Cited by in F6Publishing: 47] [Article Influence: 10.5] [Reference Citation Analysis]
237 Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, Lowell JA, Shenoy S, Darcy MD, Brown DB. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg. 2008;248:617-625. [PMID: 18936575 DOI: 10.1097/sla.0b013e31818a07d4] [Cited by in Crossref: 59] [Cited by in F6Publishing: 78] [Article Influence: 4.2] [Reference Citation Analysis]
238 Tai CJ, Wang WC, Wang CK, Wu CH, Yang MD, Chang YJ, Jian JY, Tai CJ. Fermented wheat germ extract induced cell death and enhanced cytotoxicity of Cisplatin and 5-Fluorouracil on human hepatocellular carcinoma cells. Evid Based Complement Alternat Med 2013;2013:121725. [PMID: 24454483 DOI: 10.1155/2013/121725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
239 Yamashita Y, Takeishi K, Tsuijita E, Yoshiya S, Morita K, Kayashima H, Iguchi T, Taketomi A, Shirabe K, Maehara Y. Beneficial effects of preoperative lipiodolization for resectable large hepatocellular carcinoma (≥ 5 cm in diameter). J Surg Oncol 2012;106:498-503. [PMID: 22442003 DOI: 10.1002/jso.23098] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
240 Yang HJ, Lee JH, Lee DH, Yu SJ, Kim YJ, Yoon JH, Kim HC, Lee JM, Chung JW, Yi NJ, Lee KW, Suh KS, Lee HS. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology 2014;271:909-18. [PMID: 24520944 DOI: 10.1148/radiol.13131760] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
241 Song MJ, Bae SH, Lee JS, Lee SW, Song DS, You CR, Choi JY, Yoon SK. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. Korean J Intern Med. 2016;31:242-252. [PMID: 26874512 DOI: 10.3904/kjim.2015.112] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
242 Alwalid O, Wang Y, Fan W, Han P. Value of gadoxetic acid-enhanced MR imaging and DWI in classification, characterization and confidence in diagnosis of solid focal liver lesions. Scand J Gastroenterol 2021;56:72-80. [PMID: 33232614 DOI: 10.1080/00365521.2020.1847314] [Reference Citation Analysis]
243 Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159-1172. [PMID: 15153169 DOI: 10.1111/j.1365-2036.2004.01963.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 97] [Article Influence: 6.7] [Reference Citation Analysis]
244 Kim H, Chung JW, Choi SH, Yoon J, Lee H, Jae HJ, Lee W, Park JH. Hepatocellular Carcinoma with Internal Mammary Artery Supply: Feasibility and Efficacy of Transarterial Chemoembolization and Factors Affecting Patient Prognosis. Journal of Vascular and Interventional Radiology 2007;18:611-9. [DOI: 10.1016/j.jvir.2007.02.023] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
245 McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010;14:461-476. [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
246 Dev A, Sood A, Choudhury SR, Karmakar S. Paclitaxel nanocrystalline assemblies as a potential transcatheter arterial chemoembolization (TACE) candidate for unresectable hepatocellular carcinoma. Materials Science and Engineering: C 2020;107:110315. [DOI: 10.1016/j.msec.2019.110315] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
247 Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer 2012;1:83-93. [PMID: 24159576 DOI: 10.1159/000342405] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 13.9] [Reference Citation Analysis]
248 Chen L, Sun T, Chen S, Ren Y, Yang F, Zheng C. The efficacy of surgery in advanced hepatocellular carcinoma: a cohort study. World J Surg Oncol 2020;18:119. [PMID: 32487104 DOI: 10.1186/s12957-020-01887-8] [Reference Citation Analysis]
249 Dai Y, Jiang H, Jiang H, Zhao S, Zeng X, Sun R, Zheng R. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis. Transl Oncol 2021;14:101238. [PMID: 34628285 DOI: 10.1016/j.tranon.2021.101238] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
250 Roayaie S, Llovet JM. Liver Transplantation for Hepatocellular Carcinoma: Is Expansion of Criteria Justified? Clinics in Liver Disease 2005;9:315-28. [DOI: 10.1016/j.cld.2004.12.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
251 Liem MS, Poon RT, Lo CM, Tso WK, Fan ST. Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J Gastroenterol 2005; 11(29): 4465-4471 [PMID: 16052673 DOI: 10.3748/wjg.v11.i29.4465] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
252 Fatima S, Luk JM, Poon RT, Lee NP. Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma. Expert Rev Mol Diagn 2014;14:535-48. [PMID: 24809435 DOI: 10.1586/14737159.2014.915747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
253 Zou J, Zhu W, Meng H, Luo P, Zhang J. Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2019;13:271-9. [PMID: 30791765 DOI: 10.1080/17474124.2019.1570135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
254 Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:43-58. [PMID: 22190656 DOI: 10.1148/radiol.11110144] [Cited by in Crossref: 211] [Cited by in F6Publishing: 202] [Article Influence: 21.1] [Reference Citation Analysis]
255 Seror O, N′kontchou G, Haddar D, Dordea M, Ajavon Y, Ganne N, Trinchet JC, Beaugrand M, Sellier N. Large Infiltrative Hepatocellular Carcinomas: Treatment with Percutaneous Intraarterial Ethanol Injection Alone or in Combination with Conventional Percutaneous Ethanol Injection. Radiology 2005;234:299-309. [DOI: 10.1148/radiol.2341031008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
256 Ping Z, Jun X, Yan W, Jun Z. Anti-cancer properties of specific Chinese herbal medicines for hepatocellular carcinoma treatment. Eur J Integr Med 2020;:101215. [PMID: 33042292 DOI: 10.1016/j.eujim.2020.101215] [Reference Citation Analysis]
257 Loffroy R, Lin M, Rao P, Bhagat N, Noordhoek N, Radaelli A, Blijd J, Geschwind J. Comparing the Detectability of Hepatocellular Carcinoma by C-Arm Dual-Phase Cone-Beam Computed Tomography During Hepatic Arteriography With Conventional Contrast-Enhanced Magnetic Resonance Imaging. Cardiovasc Intervent Radiol 2012;35:97-104. [DOI: 10.1007/s00270-011-0118-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
258 Ippolito D, Pecorelli A, Querques G, Drago SG, Maino C, Franzesi CT, Hatzidakis A, Sironi S. Dynamic Computed Tomography Perfusion Imaging: Complementary Diagnostic Tool in Hepatocellular Carcinoma Assessment From Diagnosis to Treatment Follow-up. Acad Radiol 2019;26:1675-85. [PMID: 30852079 DOI: 10.1016/j.acra.2019.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
259 Osuga K, Hori S, Hiraishi K, Sugiura T, Hata Y, Higashihara H, Maeda N, Tomoda K, Nakamura H. Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres. Cardiovasc Intervent Radiol. 2008;31:1108-1116. [PMID: 18543028 DOI: 10.1007/s00270-008-9369-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
260 Abdelsalam ME, Murthy R, Avritscher R, Mahvash A, Wallace MJ, Kaseb AO, Odisio BC. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Hepatocell Carcinoma 2016;3:55-61. [PMID: 27785450 DOI: 10.2147/JHC.S92732] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
261 Rahbari NN, Koch M, Schmidt T, Motschall E, Bruckner T, Weidmann K, Mehrabi A, Büchler MW, Weitz J. Meta-Analysis of the Clamp-Crushing Technique for Transection of the Parenchyma in Elective Hepatic Resection: Back to Where We Started? Ann Surg Oncol 2009;16:630-9. [DOI: 10.1245/s10434-008-0266-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
262 Ott P. What is the Value of Country-Based Surveillance Programmes? In: Williams R, Taylor-robinson SD, editors. Clinical Dilemmas in Primary Liver Cancer. Oxford: Wiley-Blackwell; 2011. pp. 97-104. [DOI: 10.1002/9781119962205.ch14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
263 Dhanasekaran R, Talwalkar JA. Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Curr Gastroenterol Rep 2015;17:34. [PMID: 26238927 DOI: 10.1007/s11894-015-0459-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
264 El-Kady NM, Esmat G, Mahmoud EH, Darweesh SK, Mahmoud SH, Elagawy WA. Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2013;25:628-33. [PMID: 23325283 DOI: 10.1097/MEG.0b013e32835d2c4f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
265 Kalva SP, Pectasides M, Yeddula K, Ganguli S, Blaszkowsky LS, Zhu AX. Factors Affecting Survival following Chemoembolization with Doxorubicin-eluting Microspheres for Inoperable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2013;24:257-65. [DOI: 10.1016/j.jvir.2012.10.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
266 Zhuang L, Wen T, Xu M, Yang J, Wang W, Wu H, Zeng Y, Yan L, Wei Y, Li B. Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. Arch Med Sci 2017;13:1383-93. [PMID: 29181069 DOI: 10.5114/aoms.2017.71066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
267 Britten CD, Gomes AS, Wainberg ZA, Elashoff D, Amado R, Xin Y, Busuttil RW, Slamon DJ, Finn RS. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer. 2012;12:16. [PMID: 22244160 DOI: 10.1186/1471-2407-12-16] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
268 Merle P, Mornex F. [Transarterial chemoembolization and conformal radiotherapy for hepatocellular carcinoma]. Cancer Radiother 2011;15:69-71. [PMID: 21237690 DOI: 10.1016/j.canrad.2010.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
269 Hucke F, Sieghart W, Schöniger-Hekele M, Peck-Radosavljevic M, Müller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr. 2011;123:542-551. [PMID: 21800047 DOI: 10.1007/s00508-011-0033-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
270 Zhang T, Zhao YT, Wang Z, Li CR, Jin J, Jia AY, Wang SL, Song YW, Liu YP, Ren H, Fang H, Bao H, Liu XF, Yu ZH, Li YX, Wang WH. Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma. Medicine (Baltimore) 2016;95:e3789. [PMID: 27227954 DOI: 10.1097/MD.0000000000003789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
271 Cho HS, Seo JW, Kang Y, Bae EJ, Kim HJ, Chang SH, Park DJ. Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. Clin Exp Nephrol. 2011;15:714-719. [PMID: 21695415 DOI: 10.1007/s10157-011-0470-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
272 Li R, Shui L, Jia J, Wu C. Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma. Front Genet 2020;11:906. [PMID: 32922438 DOI: 10.3389/fgene.2020.00906] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
273 Della Corte CM, Viscardi G, Papaccio F, Esposito G, Martini G, Ciardiello D, Martinelli E, Ciardiello F, Morgillo F. Implication of the Hedgehog pathway in hepatocellular carcinoma. World J Gastroenterol 2017; 23(24): 4330-4340 [PMID: 28706416 DOI: 10.3748/wjg.v23.i24.4330] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
274 Colombo M, Raoul J, Lencioni R, Galle PR, Zucman-rossi J, Bañares R, Seehofer D, Neuhaus P, Johnson P. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. European Journal of Gastroenterology & Hepatology 2013;25:639-51. [DOI: 10.1097/meg.0b013e32835e33bb] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
275 Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol. 2011;197:W562-W570. [PMID: 21940527 DOI: 10.2214/ajr.10.4379] [Cited by in Crossref: 109] [Cited by in F6Publishing: 45] [Article Influence: 9.9] [Reference Citation Analysis]
276 Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol. 2009;24:806-814. [PMID: 19207681 DOI: 10.1111/j.1440-1746.2008.05728.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 95] [Article Influence: 7.5] [Reference Citation Analysis]
277 Seki A, Hori S, Kobayashi K, Narumiya S. Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience. Cardiovasc Intervent Radiol. 2011;34:557-565. [PMID: 20821211 DOI: 10.1007/s00270-010-9975-y] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
278 Huan HB, Wu LL, Lau WY, Wen XD, Zhang L, Yang DP, Wang XS, Bie P, Xia F. Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data. Oncotarget 2017;8:90291-300. [PMID: 29163828 DOI: 10.18632/oncotarget.18853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
279 Kim H, Chung JW, Choi SH, Im S, Yamasaki Y, Jun S, Jae HJ, Park JH. Augmentation of Chemotherapeutic Infusion Effect by TSU-68, an Oral Targeted Antiangiogenic Agent, in a Rabbit VX2 Liver Tumor Model. Cardiovasc Intervent Radiol 2012;35:168-75. [DOI: 10.1007/s00270-010-0081-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
280 Fu M, Shi W, Li Z, Liu H. Activation of mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC inhibitor resminostat in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2016;477:527-33. [PMID: 27144317 DOI: 10.1016/j.bbrc.2016.04.147] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
281 Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444-453. [PMID: 18525342 DOI: 10.1097/CCO.0b013e328302c9e9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
282 Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011;55:1325-31. [PMID: 21703203 DOI: 10.1016/j.jhep.2011.02.034] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 8.5] [Reference Citation Analysis]
283 Mahady SE, Charlton B, Fitzgerald P, Koorey DJ, Perry JF, Waugh RC, McCaughan GW, Strasser SI. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage? J Gastroenterol Hepatol 2010;25:1299-305. [PMID: 20594260 DOI: 10.1111/j.1440-1746.2010.06267.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
284 Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments. Visc Med. 2016;32:116-120. [PMID: 27413729 DOI: 10.1159/000445730] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
285 Yao Y, Chen J, Jiao D, Li Y, Zhou X, Han X. Elemene injection combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2019;98:e17813. [PMID: 31689867 DOI: 10.1097/MD.0000000000017813] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
286 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
287 Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, Sata M. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol 2013;6:511-9. [PMID: 24151531 DOI: 10.1593/tlo.13481] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
288 Kaibori M, Tanigawa N, Kariya S, Ikeda H, Nakahashi Y, Hirohara J, Koreeda C, Seki T, Sawada S, Okazaki K, Kwon AH. A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. Dig Dis Sci 2012;57:1404-12. [PMID: 22271410 DOI: 10.1007/s10620-012-2029-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
289 Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, Borner M, Candinas D, Saar B. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010;15:1198-1204. [PMID: 21036880 DOI: 10.1634/theoncologist.2010-0180] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
290 Merle P, Mornex F. [Nonsurgical management of hepatocellular carcinoma]. Cancer Radiother 2010;14:469-73. [PMID: 20739209 DOI: 10.1016/j.canrad.2010.07.228] [Reference Citation Analysis]
291 Lee S, Kim KA, Park MS, Choi SY. MRI Findings and Prediction of Time to Progression of Patients with Hepatocellular Carcinoma Treated with Drug-eluting Bead Transcatheter Arterial Chemoembolization. J Korean Med Sci 2015;30:965-73. [PMID: 26130962 DOI: 10.3346/jkms.2015.30.7.965] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
292 Hu H, Han XK, Long XR, Fan J, Yan ZP, Wang JH, Liu R. Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma. Oncotarget. 2016;7:58302-58314. [PMID: 27506942 DOI: 10.18632/oncotarget.11078] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
293 He X, Li J, Guo W, Liu W, Yu J, Song W, Dong L, Wang F, Yu S, Zheng Y, Chen S, Kong Y, Liu C. Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. Oncotarget 2015;6:2302-14. [PMID: 25544773 DOI: 10.18632/oncotarget.2955] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
294 Real M, Bianchi L, Vilana R, Burrel M, Rimola J. Tratamiento percutáneo e intraarterial del carcinoma hepatocelular. Radiología 2010;52:399-413. [DOI: 10.1016/j.rx.2010.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
295 Kucuk ON, Soydal C, Araz M, Ozkan E, Aras G. Evaluation of the Response to Selective Internal Radiation Therapy in Patients With Hepatocellular Cancer According to Pretreatment 99mTc-MAA Uptake. Clinical Nuclear Medicine 2013;38:252-5. [DOI: 10.1097/rlu.0b013e31828162e8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
296 Shen A, Zhang H, Tang C, Chen Y, Wang Y, Zhang C, Wu Z. Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. J Gastroenterol Hepatol. 2013;28:793-800. [PMID: 23432154 DOI: 10.1111/jgh.12162] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
297 O'Sullivan S, Cagney DN. The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. Ir J Med Sci 2018;187:887-94. [PMID: 29423821 DOI: 10.1007/s11845-018-1755-8] [Reference Citation Analysis]
298 Cabibbo G, Tremosini S, Galati G, Mazza G, Gadaleta-Caldarola G, Lombardi G, Antonucci M, Sacco R. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2014;14:831-845. [PMID: 24850249 DOI: 10.1586/14737140.2014.920694] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
299 Tarasik A, Jaroszewicz J, Januszkiewicz M. Surgical treatment of liver tumors - own experience and literature review. Clin Exp Hepatol 2017;3:1-8. [PMID: 28856283 DOI: 10.5114/ceh.2017.65498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
300 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604-11; quiz e43-44. [PMID: 23357493 DOI: 10.1016/j.cgh.2012.12.039] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
301 Riemsma RP, Bala MM, Wolff R, Kleijnen J. Percutaneous ethanol injection for liver metastases. Cochrane Database Syst Rev 2013;:CD008717. [PMID: 23728679 DOI: 10.1002/14651858.CD008717.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
302 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696 [PMID: 24998696 DOI: 10.1016/s1665-2681(19)30919-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 2.4] [Reference Citation Analysis]
303 Lee IJ, Chung JW, Kim HC, Yin YH, So YH, Jeon UB, Jae HJ, Cho BH, Park JH. Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors. J Vasc Interv Radiol. 2009;20:22-29. [PMID: 19026566 DOI: 10.1016/j.jvir.2008.09.030] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
304 Son MY, Han BH, Lee SU, Yun BC, Seo KI, Huh JD. [Gallbladder Perforation after Transarterial Chemoembolization in a Patient with a Huge Hepatocellular Carcinoma]. Korean J Gastroenterol 2020;75:351-5. [PMID: 32581207 DOI: 10.4166/kjg.2020.75.6.351] [Reference Citation Analysis]
305 Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol. 2014;60:118-126. [PMID: 24012941 DOI: 10.1016/j.jhep.2013.08.022] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 7.9] [Reference Citation Analysis]
306 Ranchal I, González R, Bello RI, Ferrín G, Hidalgo AB, Linares CI, Aguilar-Melero P, González-Rubio S, Barrera P, Marchal T, Nakayama KI, de la Mata M, Muntané J. The reduction of cell death and proliferation by p27(Kip1) minimizes DNA damage in an experimental model of genotoxicity. Int J Cancer 2009;125:2270-80. [PMID: 19672859 DOI: 10.1002/ijc.24621] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
307 Guo Y, Ren Y, Chen L, Sun T, Zhang W, Sun B, Zhu L, Xiong F, Zheng C. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma. BMC Cancer 2022;22:270. [PMID: 35287627 DOI: 10.1186/s12885-022-09325-6] [Reference Citation Analysis]
308 Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai H, Kim JK, Inaba Y, Aramaki T, Kwon SH, Yamamoto S, Okusaka T; Japan Interventional Radiology in Oncology Study Group (JIVROSG); Korea Interventional Radiology in Oncology Study Group (KIVROSG). Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. J Vasc Interv Radiol. 2013;24:490-500. [PMID: 23466316 DOI: 10.1016/j.jvir.2013.01.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
309 da Motta-Leal-Filho JM. Locoregional therapies for the treatment of locally advanced hepatocellular carcinoma. Radiol Bras 2021;54:IX-X. [PMID: 34108772 DOI: 10.1590/0100-3984.2021.54.3e3] [Reference Citation Analysis]
310 Bae SI, Yeon JE, Lee JM, Kim JH, Lee HJ, Lee SJ, Suh SJ, Yoon EL, Kim HR, Byun KS, Seo TS. A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. Clin Mol Hepatol 2012;18:321-5. [PMID: 23091814 DOI: 10.3350/cmh.2012.18.3.321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
311 Wong LL, Tsai N, Limm W, Wong L. Liver transplant for hepatocellular cancer: a treatment for the select few. Clin Transplant 2004;18:205-10. [PMID: 15016137 DOI: 10.1046/j.1399-0012.2003.00157.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
312 Facciuto ME, Koneru B, Rocca JP, Wolf DC, Kim-Schluger L, Visintainer P, Klein KM, Chun H, Marvin M, Rozenblit G. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation. Ann Surg Oncol. 2008;15:1383-1391. [PMID: 18320284 DOI: 10.1245/s10434-008-9851-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
313 Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer. 2012;1:83-93. [PMID: 24159576 DOI: 10.1159/0003424-05] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
314 Ren Y, Cao Y, Ma H, Kan X, Zhou C, Liu J, Shi Q, Feng G, Xiong B, Zheng C. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study. BMC Cancer 2019;19:983. [PMID: 31640620 DOI: 10.1186/s12885-019-6237-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
315 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
316 Shin J, Yu JH, Jin YJ, Suh YJ, Kim DH, Byun S, Lee JW. Effective therapeutic options for elderly patients with hepatocellular carcinoma: A nationwide cohort study. Medicine (Baltimore) 2019;98:e16150. [PMID: 31348228 DOI: 10.1097/MD.0000000000016150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019;28:228-235. [PMID: 30851906 DOI: 10.1016/j.suronc.2019.01.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
318 Yan L, Liang X, Huang H, Zhang G, Liu T, Zhang J, Chen Z, Zhang Z, Chen Y. S-Adenosylmethionine Affects Cell Cycle Pathways and Suppresses Proliferation in Liver Cells. J Cancer 2019;10:4368-79. [PMID: 31413757 DOI: 10.7150/jca.25422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
319 Cai CM, Xiao X, Wu BH, Wei BF, Han ZG. Targeting endogenous DLK1 exerts antitumor effect on hepatocellular carcinoma through initiating cell differentiation. Oncotarget 2016;7:71466-76. [PMID: 27683116 DOI: 10.18632/oncotarget.12214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
320 Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12003-12021 [PMID: 26576088 DOI: 10.3748/wjg.v21.i42.12003] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
321 Han JH, Kim DG, Chung HT, Paek SH, Park CK, Kim CY, Kim YH, Jung HW. Stereotactic radiosurgery for brain metastases from hepatocellular carcinoma. J Neurooncol 2013;115:45-51. [PMID: 23813231 DOI: 10.1007/s11060-013-1192-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
322 Yu HP, Xie JM, Li B, Sun YH, Gao QG, Ding ZH, Wu HR, Qin ZH. TIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathway. Sci Rep 2015;5:9853. [PMID: 25928429 DOI: 10.1038/srep09853] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
323 Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F, PRECISION ITALIA STUDY GROUP. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255-264. [PMID: 24937669 DOI: 10.1038/bjc.2014.199] [Cited by in Crossref: 264] [Cited by in F6Publishing: 235] [Article Influence: 33.0] [Reference Citation Analysis]
324 Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 2019;72:28-36. [PMID: 30447470 DOI: 10.1016/j.ctrv.2018.11.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 18.0] [Reference Citation Analysis]
325 Xu LF, Sun HL, Chen YT, Ni JY, Chen D, Luo JH, Zhou JX, Hu RM, Tan QY. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013;28:456-463. [PMID: 23216261 DOI: 10.1111/jgh.12088] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
326 McKinley SK, Chawla A, Ferrone CR. Inoperable Biliary Tract and Primary Liver Tumors: Palliative Treatment Options. Surg Oncol Clin N Am 2019;28:745-62. [PMID: 31472917 DOI: 10.1016/j.soc.2019.06.009] [Reference Citation Analysis]
327 Zhang Y, Zheng K, Yan H, Jin G, Shao C, Zhou X, Zhou Y, He T. Growth inhibition and apoptosis induced by 6-fluoro-3-formylchromone in hepatocellular carcinoma. BMC Gastroenterol 2014;14:62. [PMID: 24708487 DOI: 10.1186/1471-230X-14-62] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
328 Lord R, Suddle A, Ross PJ. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. Int J Clin Pract. 2011;65:182-188. [PMID: 21235699 DOI: 10.1111/j.1742-1241.2010.02545.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
329 Byun CS, Hwang S, Woo SH, Kim MY, Lee JS, Lee JI, Kong JH, Bae KS, Park IH, Kim SH, Eom YW. Adipose Tissue-Derived Mesenchymal Stem Cells Suppress Growth of Huh7 Hepatocellular Carcinoma Cells via Interferon (IFN)-β-Mediated JAK/STAT1 Pathway in vitro. Int J Med Sci 2020;17:609-19. [PMID: 32210710 DOI: 10.7150/ijms.41354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
330 Kim H, Chung JW, Jae HJ, Jeon UB, Son KR, Park JH. Hepatocellular Carcinoma: Prediction of Blood Supply from an Internal Mammary Artery with Multi–Detector Row CT. Journal of Vascular and Interventional Radiology 2008;19:1419-25. [DOI: 10.1016/j.jvir.2008.06.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
331 Teng W, Hsieh YC, Lui KW, Chen WT, Hung CF, Huang CH, Chen YC, Jeng WJ, Lin CC, Lin CY, Lin SM, Sheen IS. Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization. J Viral Hepat 2017;24:1160-7. [PMID: 28643457 DOI: 10.1111/jvh.12745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
332 Kim DY, Lee HW, Kang W, Kim GM, Won JY, Yun M. Metabolic activity assessment by 18 F-fluorodeoxyglucose positron emission tomography in patients with hepatocellular carcinoma undergoing Yttrium-90 transarterial radioembolization. J Gastroenterol Hepatol 2021;36:1679-84. [PMID: 33226706 DOI: 10.1111/jgh.15357] [Reference Citation Analysis]
333 Ahmed M, Moussa M, Goldberg SN. Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. Chem Phys Lipids. 2012;165:424-437. [PMID: 22197685 DOI: 10.1016/j.chemphyslip.2011.12.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
334 Lungren MP, Towbin AJ, Roebuck DJ, Monroe EJ, Gill AE, Thakor A, Towbin RB, Cahill AM, Matthew Hawkins C. Role of interventional radiology in managing pediatric liver tumors : Part 1: Endovascular interventions. Pediatr Radiol. 2018;48:555-564. [PMID: 29362840 DOI: 10.1007/s00247-018-4068-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
335 Lee KH, Liapi E, Ventura VP, Buijs M, Vossen JA, Vali M, Geschwind JF. Evaluation of different calibrated spherical polyvinyl alcohol microspheres in transcatheter arterial chemoembolization: VX2 tumor model in rabbit liver. J Vasc Interv Radiol. 2008;19:1065-1069. [PMID: 18589321 DOI: 10.1016/j.jvir.2008.02.023] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
336 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol 2013; 5(6): 302-310 [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
337 Burgmans MC, van Erkel AR, Too CW, Coenraad M, Lo RH, Tan BS. Pilot study evaluating catheter-directed contrast-enhanced ultrasound compared to catheter-directed computed tomography arteriography as adjuncts to digital subtraction angiography to guide transarterial chemoembolization. Clin Radiol. 2014;69:1056-1061. [PMID: 25017449 DOI: 10.1016/j.crad.2014.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
338 Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol 2015; 21(36): 10327-10335 [PMID: 26420959 DOI: 10.3748/wjg.v21.i36.10327] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 50] [Article Influence: 7.7] [Reference Citation Analysis]
339 Wang C, Gao W, Feng M, Pastan I, Ho M. Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. Oncotarget 2017;8:32450-60. [PMID: 27419635 DOI: 10.18632/oncotarget.10592] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
340 Zhou Z, Lu X, Zhu P, Zhu W, Mu X, Qu R, Li M. VCC-1 over-expression inhibits cisplatin-induced apoptosis in HepG2 cells. Biochemical and Biophysical Research Communications 2012;420:336-42. [DOI: 10.1016/j.bbrc.2012.02.160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
341 Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, Mamone G, Vizzini G, Luca A, Gridelli B. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol 2007; 13(21): 2952-2955 [PMID: 17589945 DOI: 10.3748/wjg.v13.i21.2952] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
342 Murray LJ, Dawson LA. Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Semin Radiat Oncol. 2017;27:247-255. [PMID: 28577832 DOI: 10.1016/j.semradonc.2017.02.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 9.6] [Reference Citation Analysis]
343 Bharadwaj M, Roy G, Dutta K, Misbah M, Husain M, Hussain S. Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. Cancer Metastasis Rev. 2013;32:229-268. [PMID: 23114844 DOI: 10.1007/s10555-012-9412-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
344 Welker MW, Lubomierski N, Gog C, Herrmann E, Engels K, Vogl TJ, Bechstein WO, Zeuzem S, Trojan J. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. J Chemother 2010;22:205-11. [PMID: 20566428 DOI: 10.1179/joc.2010.22.3.205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
345 Guiu B, Deschamps F, Boulin M, Boige V, Malka D, Ducreux M, Hillon P, de Baère T. Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Cardiovasc Intervent Radiol. 2012;35:1102-1108. [PMID: 22009578 DOI: 10.1007/s00270-011-0293-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
346 Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg 2007;11:1636-46; discussion 1646. [PMID: 17912593 DOI: 10.1007/s11605-007-0315-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
347 Boulin M, Ciboulet A, Guiu B, Maillard E, Bonnetain F, Minello A, Gagnaire A, Lepage C, Krause D, Hillon P, Bedenne L, Cercueil JP, Chauffert B, Jouve JL. Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. Dig Liver Dis 2011;43:905-11. [PMID: 21802381 DOI: 10.1016/j.dld.2011.06.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
348 Schicho A, Hellerbrand C, Krüger K, Beyer LP, Wohlgemuth W, Niessen C, Hohenstein E, Stroszczynski C, Pereira PL, Wiggermann P. Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels. J Clin Transl Hepatol 2016;4:288-92. [PMID: 28097096 DOI: 10.14218/JCTH.2016.00058] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
349 Toyama T, Nitta N, Ohta S, Tanaka T, Nagatani Y, Takahashi M, Murata K, Shiomi H, Naka S, Kurumi Y, Tani T, Tabata Y. Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma. Jpn J Radiol 2012;30:62-8. [PMID: 22194039 DOI: 10.1007/s11604-011-0010-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
350 Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Ignacio Bilbao J, Maria Ettorre G, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Thorsten Hoffmann R, Izzo F, Iñarrairaegui M, Ludovico Maini C, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Franz Jakobs T, Lastoria S; on behalf of the European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology 2011;54:868-78. [DOI: 10.1002/hep.24451] [Cited by in Crossref: 401] [Cited by in F6Publishing: 366] [Article Influence: 36.5] [Reference Citation Analysis]
351 Shibata T, Shibata T, Maetani Y, Isoda H, Hiraoka M. Radiofrequency ablation for small hepatocellular carcinoma: prospective comparison of internally cooled electrode and expandable electrode. Radiology. 2006;238:346-353. [PMID: 16373776 DOI: 10.1148/radiol.2381041848] [Cited by in Crossref: 105] [Cited by in F6Publishing: 77] [Article Influence: 6.6] [Reference Citation Analysis]
352 Giacomin A, Sergio A, Vanin V, Tartaro P, Paccagnella D, Mazzucco M, Farinati F. Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era. Hepatology Research 2010;40:153-60. [DOI: 10.1111/j.1872-034x.2009.00588.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
353 Huang DJ, Li YH, Luo YC, Huang JZ, He HY. Effective hepatic artery chemoembolization for advanced hepatocellular carcinoma with multiple tumor thrombi and pulmonary metastases: A case report. Oncol Lett 2016;12:2103-6. [PMID: 27602147 DOI: 10.3892/ol.2016.4846] [Reference Citation Analysis]
354 Panaro F, Ramos J, Gallix B, Mercier G, Herrero A, Niampa H, Pageaux G, Navarro F. Hepatic artery complications following liver transplantation. Does preoperative chemoembolization impact the postoperative course? Clin Transplant 2014;28:598-605. [DOI: 10.1111/ctr.12358] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
355 Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, Liu J, Cui Y, Bian X, Bie P, Qian C. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Letters 2011. [DOI: 10.1016/j.canlet.2011.06.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 93] [Article Influence: 2.0] [Reference Citation Analysis]
356 Wang K, Fan Y, Chen G, Wang Z, Kong D, Zhang P. MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models. Biochemical and Biophysical Research Communications 2016;474:330-7. [DOI: 10.1016/j.bbrc.2016.04.099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
357 Kalra N, Gupta P, Chawla Y, Khandelwal N. Locoregional treatment for hepatocellular carcinoma: The best is yet to come. World J Radiol 2015; 7(10): 306-318 [PMID: 26516427 DOI: 10.4329/wjr.v7.i10.306] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
358 Liu J, Cui X, Qu L, Hua L, Wu M, Shen Z, Lu C, Ni R. Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma. Exp Mol Pathol 2016;101:58-65. [PMID: 27302463 DOI: 10.1016/j.yexmp.2016.06.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
359 Bholee AK, Peng K, Zhou Z, Chen J, Xu L, Zhang Y, Chen M. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. Clin Transl Oncol. 2017;19:844-852. [PMID: 28070766 DOI: 10.1007/s12094-016-1611-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
360 Lin X, Peng Z, Fu X, Liu C, Xu Y, Ji W, Fan J, Chen L, Fang L, Huang Y, Su C. Volatile oil from Saussurea lappa exerts antitumor efficacy by inhibiting epithelial growth factor receptor tyrosine kinase-mediated signaling pathway in hepatocellular carcinoma. Oncotarget 2016;7:79761-73. [PMID: 27806329 DOI: 10.18632/oncotarget.12962] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
361 Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs. 2004;13:1555-1568. [PMID: 15566313 DOI: 10.1517/13543784.13.12.1555] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
362 Cao W, Li JH, Feng DY, Wan Y, Liu YF, Yang QF, Cheng JW, Zhao SY, Zhang HX. Effect of transarterial pulsed perfusion with heated saline on tumor vascular permeability in a rabbit VX2 liver tumor model. Eur J Radiol 2012;81:e209-16. [PMID: 21345630 DOI: 10.1016/j.ejrad.2011.01.108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
363 Sim HW, Knox J, Dawson LA. An Update on Randomized Clinical Trials in Hepatocellular Carcinoma. Surg Oncol Clin N Am 2017;26:647-66. [PMID: 28923223 DOI: 10.1016/j.soc.2017.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
364 Guan YS, Liu Y, Zhou XP, Li X, He Q, Sun L. p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma. Gut 2005;54:1318-9. [PMID: 15879012 DOI: 10.1136/gut.2005.069237] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
365 Chong DQ, Tan IB, Choo SP, Toh HC. The evolving landscape of therapeutic drug development for hepatocellular carcinoma. Contemp Clin Trials 2013;36:605-15. [PMID: 23591326 DOI: 10.1016/j.cct.2013.03.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
366 Keng VW, Largaespada DA, Villanueva A. Why men are at higher risk for hepatocellular carcinoma? J Hepatol. 2012;57:453-454. [PMID: 22425699 DOI: 10.1016/j.jhep.2012.03.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
367 Farinati F, Vanin V, Giacomin A, Pozzan C, Cillo U, Vitale A, Di Nolfo AM, Del Poggio P, Benvegnu’ L, Rapaccini G. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. Liver Int. 2015;35:223-231. [PMID: 25074434 DOI: 10.1111/liv.12649] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
368 Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, Pinelopi M, Burroughs AK. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2008;8:1623-1641. [PMID: 18925854 DOI: 10.1586/14737140.8.10.1623] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
369 Park SE, Cho SB, Baek HJ, Moon JI, Ryu KH, Ha JY, Lee S, Won J, Ahn JH, Kim R, Choi SY. Clinical experience with distal transradial access for endovascular treatment of various noncoronary interventions in a multicenter study. PLoS One 2020;15:e0237798. [PMID: 32822396 DOI: 10.1371/journal.pone.0237798] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
370 Dorn DP, Bryant MK, Zarzour J, Smith JK, Redden DT, Saddekni S, Abdel Aal AK, Gray S, White J, Eckhoff DE, DuBay DA. Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. HPB (Oxford) 2014;16:648-55. [PMID: 25072067 DOI: 10.1111/hpb.12194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
371 Shen L, Zhang Z, Wang T, Yang X, Huang R, Quan D. Reversed lipid-based nanoparticles dispersed in oil for malignant tumor treatment via intratumoral injection. Drug Deliv 2017;24:857-66. [PMID: 28549383 DOI: 10.1080/10717544.2017.1330373] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
372 Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12(10): 738-753 [PMID: 33200013 DOI: 10.4254/wjh.v12.i10.738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
373 Jang JH, Lee JW, Hong JT, Jin YJ. Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy. J Hepatocell Carcinoma 2015;2:123-9. [PMID: 27508201 DOI: 10.2147/JHC.S44380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
374 Bala MM, Riemsma RP, Wolff R, Kleijnen J. Cryotherapy for liver metastases. Cochrane Database Syst Rev 2013;:CD009058. [PMID: 23740609 DOI: 10.1002/14651858.CD009058.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
375 Wu L, Yang YF, Ge NJ, Shen SQ, Liang J, Wang Y, Zhou WP, Shen F, Wu MC. Hepatic artery injection of ¹³¹I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study. Eur J Nucl Med Mol Imaging. 2012;39:1306-1315. [PMID: 22588627 DOI: 10.1007/s00259-012-2145-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
376 Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312-1327. [PMID: 18821591 DOI: 10.1002/hep.22506] [Cited by in Crossref: 747] [Cited by in F6Publishing: 709] [Article Influence: 53.4] [Reference Citation Analysis]
377 Song DS, Choi JY, Yoo SH, Kim HY, Song MJ, Bae SH, Yoon SK, Chun HJ, Choi BG, Lee HG. DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study. Gut Liver 2013;7:89-95. [PMID: 23424047 DOI: 10.5009/gnl.2013.7.1.89] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
378 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol 2017;67:173-83. [PMID: 28323121 DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
379 Han CJ. Recent developments in systemic chemotherapy for hepatocellular carcinoma. Korean J Hepatol 2008;14:4. [DOI: 10.3350/kjhep.2008.14.1.4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
380 Sanchez W, Talwalkar JA. Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am 2006;35:201-19. [PMID: 16530121 DOI: 10.1016/j.gtc.2005.12.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
381 Vande Lune P, Abdel Aal AK, Klimkowski S, Zarzour JG, Gunn AJ. Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. J Clin Transl Hepatol 2018;6:175-88. [PMID: 29951363 DOI: 10.14218/JCTH.2017.00045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
382 Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Göttlicher M, Gregor M, Lauer UM, Bitzer M. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. Journal of Hepatology 2005;42:210-7. [DOI: 10.1016/j.jhep.2004.10.020] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 4.1] [Reference Citation Analysis]
383 Makramalla A, Itri JN, Choe KA, Ristagno RL. Transarterial Therapies for Hepatocellular Carcinoma. Seminars in Roentgenology 2016;51:95-105. [DOI: 10.1053/j.ro.2016.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
384 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
385 Thuluvath PJ, To C, Amjad W. Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. Am J Gastroenterol 2021;116:57-67. [PMID: 33110015 DOI: 10.14309/ajg.0000000000000999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
386 Tanaka H, Okamoto K, Sato Y, Tanaka T, Tomonari T, Nakamura F, Fujino Y, Mitsui Y, Miyamoto H, Muguruma N, Morita A, Ikushima H, Takayama T. Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma. J Gastroenterol 2020;55:1072-86. [DOI: 10.1007/s00535-020-01705-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
387 Inaba Y, Arai Y, Sone M, Aramaki T, Osuga K, Tanaka H, Kanemasa K. Clinical trial for development of a steerable microcatheter. Minimally Invasive Therapy & Allied Technologies 2019;28:1-5. [DOI: 10.1080/13645706.2018.1467458] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
388 Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2012;4:188-96. [PMID: 23139708 DOI: 10.3892/etm.2012.569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
389 Leal JN, Gonen M, Covey AM, Erinjeri JP, Getrajdman G, Sofocleous CT, D'Angelica M, DeMatteo RP, Abou-Alfa GK, Jarnagin WR, Fong Y, Brown KT. Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. J Vasc Interv Radiol 2015;26:1112-21. [PMID: 26038273 DOI: 10.1016/j.jvir.2015.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
390 Takayasu K. Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. Oncology 2011;81 Suppl 1:105-10. [PMID: 22212943 DOI: 10.1159/000333269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
391 Aslam A, Kamath A, Spieler B, Maschiocchi M, Sabottke CF, Chernyak V, Lewis SC. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents. Abdom Radiol (NY) 2021;46:3565-78. [PMID: 33856509 DOI: 10.1007/s00261-021-03076-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
392 Namur J, Wassef M, Millot J, Lewis AL, Manfait M, Laurent A. Drug-eluting Beads for Liver Embolization: Concentration of Doxorubicin in Tissue and in Beads in a Pig Model. Journal of Vascular and Interventional Radiology 2010;21:259-67. [DOI: 10.1016/j.jvir.2009.10.026] [Cited by in Crossref: 84] [Cited by in F6Publishing: 71] [Article Influence: 7.0] [Reference Citation Analysis]
393 Yamada R, Gayed A. Adding Sorafenib-eluting Microspheres to TACE: The Next Step in Hepatocellular Carcinoma Treatment. Radiol Imaging Cancer 2021;3:e200132. [PMID: 33778759 DOI: 10.1148/rycan.2021200132] [Reference Citation Analysis]
394 Pinato DJ, Murray SM, Forner A, Kaneko T, Fessas P, Toniutto P, Mínguez B, Cacciato V, Avellini C, Diaz A, Boyton RJ, Altmann DM, Goldin RD, Akarca AU, Marafioti T, Mauri FA, Casagrande E, Grillo F, Giannini E, Bhoori S, Mazzaferro V. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer 2021;9:e003311. [PMID: 34593621 DOI: 10.1136/jitc-2021-003311] [Reference Citation Analysis]
395 Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624-1636. [PMID: 29107679 DOI: 10.1016/s1470-2045(17)30683-6] [Cited by in Crossref: 300] [Cited by in F6Publishing: 133] [Article Influence: 60.0] [Reference Citation Analysis]
396 Ha Y, Han S, Shim JH, Ko GY, Yoon HK, Sung KB, Lee D, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. J Vasc Interv Radiol 2015;26:1093-1101.e1. [PMID: 26077020 DOI: 10.1016/j.jvir.2015.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
397 Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(15): 4115-4127 [PMID: 24764650 DOI: 10.3748/wjg.v20.i15.4115] [Cited by in CrossRef: 237] [Cited by in F6Publishing: 220] [Article Influence: 29.6] [Reference Citation Analysis]
398 Kim YH, Kim do Y. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. Oncology. 2013;84 Suppl 1:34-39. [PMID: 23428856 DOI: 10.1159/000345887] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
399 Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2015;35 Suppl 1:129-138. [PMID: 25529098 DOI: 10.1111/liv.12713] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
400 Kumar A, Srivastava DN, Chau TT, Long HD, Bal C, Chandra P, Chien le T, Hoa NV, Thulkar S, Sharma S, Tam le H, Xuan TQ, Canh NX, Pant GS, Bandopadhyaya GP. Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial. Radiology 2007;243:509-19. [PMID: 17456873 DOI: 10.1148/radiol.2432051246] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
401 Bucalau AM, Tancredi I, Verset G. In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play? Cancers (Basel) 2021;13:5129. [PMID: 34680278 DOI: 10.3390/cancers13205129] [Reference Citation Analysis]
402 Wang Y, Deng B, Tang W, Liu T, Shen X. TGF-β1 Secreted by Hepatocellular Carcinoma Induces the Expression of the Foxp3 Gene and Suppresses Antitumor Immunity in the Tumor Microenvironment. Dig Dis Sci 2013;58:1644-52. [DOI: 10.1007/s10620-012-2550-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
403 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(20): 5935-5950 [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 90] [Article Influence: 10.9] [Reference Citation Analysis]
404 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
405 Lorenz K, Brauckhoff M, Behrmann C, Sekulla C, Ukkat J, Brauckhoff K, Gimm O, Dralle H. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 2005;138:986-93. [DOI: 10.1016/j.surg.2005.09.020] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
406 Labadie KP, Ludwig AD, Lehnert AL, Hamlin DK, Kenoyer AL, Sullivan KM, Daniel SK, Mihailovic TN, Sham JG, Orozco JJ, Yeung RS, Chen DL, Wilbur DS, Miyaoka RS, Park JO. Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma. Sci Rep 2021;11:3731. [PMID: 33580090 DOI: 10.1038/s41598-021-82172-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
407 Sato K, Lewandowski RJ, Bui JT, Omary R, Hunter RD, Kulik L, Mulcahy M, Liu D, Chrisman H, Resnick S. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29:522-529. [PMID: 16729228 DOI: 10.1007/s00270-005-0171-4] [Cited by in Crossref: 158] [Cited by in F6Publishing: 156] [Article Influence: 9.9] [Reference Citation Analysis]
408 Ng KK, Vauthey J, Pawlik TM, Lauwers GY, Regimbeau J, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney DM, Ng IO, Fan ST, Poon RT. Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database. Ann Surg Oncol 2005;12:364-73. [DOI: 10.1245/aso.2005.06.004] [Cited by in Crossref: 167] [Cited by in F6Publishing: 81] [Article Influence: 9.8] [Reference Citation Analysis]
409 Lang BH, Poon RT, Fan ST, Wong J. Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding. Am J Gastroenterol. 2004;99:2158-2165. [PMID: 15554997 DOI: 10.1111/j.1572-0241.2004.40336.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
410 Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Prete SD, De Vita F, Russo A, Caraglia M. MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. Molecular Therapy - Nucleic Acids 2015;4:e233. [DOI: 10.1038/mtna.2015.8] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 13.0] [Reference Citation Analysis]
411 Chang PY, Chung CH, Chang WC, Lin CS, Lin HH, Dai MS, Ho CL, Chien WC. The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study. PLoS One 2019;14:e0216828. [PMID: 31125347 DOI: 10.1371/journal.pone.0216828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
412 Seki A, Hori S, Shimono C. Management of vascular lake phenomenon on angiography during chemoembolization with superabsorbent polymer microspheres. Jpn J Radiol. 2015;33:741-748. [PMID: 26493810 DOI: 10.1007/s11604-015-0486-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
413 Bae HM, Lee JH, Yoon JH, Kim YJ, Heo DS, Lee HS. Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. BMC Cancer. 2011;11:435. [PMID: 21985636 DOI: 10.1186/1471-2407-11-435] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
414 Georgiades C. Chemoembolization for Lung Neoplasms: Exuberant Expectations versus Meticulous Investigation. Radiology 2021;301:485-6. [PMID: 34463557 DOI: 10.1148/radiol.2021211488] [Reference Citation Analysis]
415 Woo HY, Jang JW, Choi JY, Bae SH, You CR, Rha SE, Lee YJ, Yoon SK, Lee CD. Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol. 2010;45:332-339. [PMID: 20001605 DOI: 10.3109/00365520903456573] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
416 Graf D, Vallböhmer D, Knoefel WT, Kröpil P, Antoch G, Sagir A, Häussinger D. Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med. 2014;25:430-437. [PMID: 24666568 DOI: 10.1016/j.ejim.2014.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
417 Giraud P, Lerouge D, Latorzeff I, Mirabel X, Dohan A, Mordant P, Barry de Longchamps N. [Stereotaxic radiotherapy of primary extracranial tumors]. Cancer Radiother 2020;24:513-22. [PMID: 32830055 DOI: 10.1016/j.canrad.2020.06.020] [Reference Citation Analysis]
418 Sangro B. Chemoembolization and radioembolization. Best Practice & Research Clinical Gastroenterology 2014;28:909-19. [DOI: 10.1016/j.bpg.2014.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
419 Cho CW, Choi GS, Kim JM, Kwon CHD, Kim DJ, Joh JW. Clinical usefulness of transarterial chemoembolization response prior to liver transplantation as predictor of optimal timing for living donor liver transplantation. Ann Surg Treat Res 2018;95:111-20. [PMID: 30079328 DOI: 10.4174/astr.2018.95.2.111] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
420 Ni J, Liu S, Xu L, Sun H, Chen Y. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013;139:653-9. [DOI: 10.1007/s00432-012-1369-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
421 Hirokawa F, Komeda K, Taniguchi K, Asakuma M, Shimizu T, Inoue Y, Kagota S, Tomioka A, Yamamoto K, Uchiyama K. Is Postoperative Adjuvant Transcatheter Arterial Infusion Therapy Effective for Patients with Hepatocellular Carcinoma who Underwent Hepatectomy? A Prospective Randomized Controlled Trial. Ann Surg Oncol 2020;27:4143-52. [PMID: 32500344 DOI: 10.1245/s10434-020-08699-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
422 Géraud C, Mogler C, Runge A, Evdokimov K, Lu S, Schledzewski K, Arnold B, Hämmerling G, Koch PS, Breuhahn K, Longerich T, Marx A, Weiss C, Damm F, Schmieder A, Schirmacher P, Augustin HG, Goerdt S. Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilin-2 expression in peri-tumourous liver correlates with increased survival. Liver Int 2013;33:1428-40. [DOI: 10.1111/liv.12262] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
423 Zhou Q, Tuo F, Li R, Wang X, Wang J, Huang Z, Chen M, Huang J. Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma. Front Oncol 2020;10:578763. [PMID: 33251141 DOI: 10.3389/fonc.2020.578763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
424 Tang C, Shen J, Feng W, Bao Y, Dong X, Dai Y, Zheng Y, Zhang J. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Medicine (Baltimore) 2016;95:e3754. [PMID: 27196501 DOI: 10.1097/MD.0000000000003754] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 5.2] [Reference Citation Analysis]
425 Yi Y, Zhang Y, Wei Q, Zhao L, Han J, Song Y, Ding Y, Lu G, Liu J, Ding H, Dai F, Tang X. Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. Chin J Cancer Res 2014;26:112-8. [PMID: 24653633 DOI: 10.3978/j.issn.1000-9604.2014.02.09] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
426 Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:13051. [PMID: 34884853 DOI: 10.3390/ijms222313051] [Reference Citation Analysis]
427 Gerard B, Bleiberg H. Treatment of hepatocarcinoma. Curr Oncol Rep 2004;6:184-91. [PMID: 15066229 DOI: 10.1007/s11912-004-0048-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
428 Reig M, Berzigotti A, Bruix J. If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection? Liver Int 2013;33:1454-6. [PMID: 24099263 DOI: 10.1111/liv.12273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
429 Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2014;23:289-311. [DOI: 10.1016/j.soc.2013.10.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
430 Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116:1305-1314. [PMID: 20066715 DOI: 10.1002/cncr.24884] [Cited by in Crossref: 120] [Cited by in F6Publishing: 116] [Article Influence: 10.0] [Reference Citation Analysis]
431 Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 2009;7:41. [PMID: 19698189 DOI: 10.1186/1741-7015-7-41] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 6.9] [Reference Citation Analysis]
432 Xiao EH, Guo D, Bian DJ. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. World J Gastroenterol 2009; 15(36): 4582-4586 [PMID: 19777619 DOI: 10.3748/wjg.15.4582] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
433 Choi HJ, Cho BC, Sohn JH, Shin SJ, Kim SH, Kim JH, Yoo NC. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol. 2009;91:307-313. [PMID: 18949445 DOI: 10.1007/s11060-008-9713-3] [Cited by in Crossref: 81] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
434 Ogawa K, Kamimura K, Watanabe Y, Motai Y, Kumaki D, Seki R, Sakamaki A, Abe S, Kawai H, Suda T, Yamagiwa S, Terai S. Effect of double platinum agents, combination of miriplatin-transarterial oily chemoembolization and cisplatin-hepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases. World J Clin Cases 2017; 5(6): 238-246 [PMID: 28685137 DOI: 10.12998/wjcc.v5.i6.238] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
435 Garrean S, Hering J, Helton WS, Espat NJ. A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors. Am J Surg 2007;194:79-88. [PMID: 17560915 DOI: 10.1016/j.amjsurg.2006.11.025] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
436 Wu PZ, Zhou J, Zhang YW. Gelatin sponge microparticles for the treatment of the spontaneous rupture of hepatocellular carcinoma hemorrhage. Exp Ther Med 2016;12:2201-7. [PMID: 27698712 DOI: 10.3892/etm.2016.3573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
437 Qi X, Liu L, Wang D, Li H, Su C, Guo X. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Oncotarget 2015;6:36838-59. [PMID: 26451613 DOI: 10.18632/oncotarget.5426] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
438 Kath N, Handels H, Mastmeyer A. Robust GPU-based virtual reality simulation of radio-frequency ablations for various needle geometries and locations. Int J Comput Assist Radiol Surg 2019;14:1825-35. [PMID: 31338680 DOI: 10.1007/s11548-019-02033-w] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
439 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
440 Marelli L, Shusang V, Buscombe JR, Cholongitas E, Stigliano R, Davies N, Tibballs J, Patch D, Meyer T, Burroughs AK. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med 2009;50:871-7. [PMID: 19443599 DOI: 10.2967/jnumed.108.060558] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
441 Choi GH, Kim DH, Kang CM, Kim KS, Choi JS, Lee WJ, Kim BR. Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma? World J Surg 2007;31:2370-7. [PMID: 17912587 DOI: 10.1007/s00268-007-9245-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
442 Huang BS, Tsang NM, Lin SM, Lin DY, Lien JM, Lin CC, Chen WT, Chen WY, Hong JH. High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities. Oncol Lett 2013;6:1514-20. [PMID: 24179551 DOI: 10.3892/ol.2013.1582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
443 Lopez PM, Villanueva A, Roayaie S, Llovet JM. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl. 2006;12:1747-1754. [PMID: 17133591 DOI: 10.1002/lt.21018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
444 Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: A review of literature. World J Gastroenterol 2014; 20(15): 4141-4150 [PMID: 24764652 DOI: 10.3748/wjg.v20.i15.4141] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
445 Monsky WL, Kim I, Loh S, Li CS, Greasby TA, Deutsch LS, Badawi RD. Semiautomated segmentation for volumetric analysis of intratumoral ethiodol uptake and subsequent tumor necrosis after chemoembolization. AJR Am J Roentgenol 2010;195:1220-30. [PMID: 20966331 DOI: 10.2214/AJR.09.3964] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
446 Lee TK, Castilho A, Ma S, Ng IO. Liver cancer stem cells: implications for a new therapeutic target. Liver Int. 2009;29:955-965. [PMID: 19490415 DOI: 10.1111/j.1478-3231.2009.02040.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
447 Lee V, Seong J, Yoon S, Wong T, Wang B, Zhang J, Chiang C, Ho P, Dawson L. Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. Clinical Oncology 2019;31:560-9. [DOI: 10.1016/j.clon.2019.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
448 Ou MC, Liu YS, Chuang MT, Lin CY, Huang LT, Lin CY. Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma. Clin Radiol 2019;74:295-300. [PMID: 30635122 DOI: 10.1016/j.crad.2018.12.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
449 Watanabe K, Kodama Y, Sakurai Y, Yamaguchi B, Yamasaki K, Ishiguro A, Ambo Y. Adrenocortical carcinoma with multiple liver metastases controlled by bland transarterial embolization and surgery resulting in long-term survival. Radiology Case Reports 2022;17:1095-8. [DOI: 10.1016/j.radcr.2022.01.052] [Reference Citation Analysis]
450 Storman D, Swierz MJ, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM. Electrocoagulation for liver metastases. Cochrane Database Syst Rev 2021;1:CD009497. [PMID: 33507555 DOI: 10.1002/14651858.CD009497.pub3] [Reference Citation Analysis]
451 Scher N, Janoray G, Riet FG, Le Bayon AG, Debbi K, Lévy S, Louisot P, Garaud P, Chajon E, Barillot I, Salamé É, de Crevoisier R, Chapet S, Calais G. [Stereotactic body radiation therapy for hepatocellular carcinoma: Results from a retrospective multicentre study]. Cancer Radiother 2019;23:104-15. [PMID: 30952560 DOI: 10.1016/j.canrad.2018.07.138] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
452 Reso A, Ball CG, Sutherland FR, Bathe O, Dixon E. Rupture and intra-peritoneal bleeding of a hepatocellular carcinoma after a transarterial chemoembolization procedure: a case report. Cases J. 2009;2:68. [PMID: 19154593 DOI: 10.1186/1757-1626-2-68] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
453 Khan AS, Fowler KJ, Chapman WC. Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 2014; 20(41): 15007-15017 [PMID: 25386049 DOI: 10.3748/wjg.v20.i41.15007] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
454 Dawson LA. The evolving role of radiation therapy in hepatocellular carcinoma. Cancer Radiother 2008;12:96-101. [PMID: 18289910 DOI: 10.1016/j.canrad.2007.12.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
455 Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin Liver Dis. 2013;17:375-397. [PMID: 23905811 DOI: 10.1016/j.cld.2013.05.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
456 Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 2015;21:115-21. [PMID: 26157747 DOI: 10.3350/cmh.2015.21.2.115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
457 Yildiz I, Deniz S, Ozer A, Caliskan K. Trans-Arterial Chemoembolization with 50 μm Degradable Starch Microspheres Versus 300–500 μm Drug Eluting Beads in Hepatocellular Carcinoma: A Comparative Analysis of Initial Treatment Outcomes. Journal of the Belgian Society of Radiology 2022;106:10. [DOI: 10.5334/jbsr.2594] [Reference Citation Analysis]
458 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 28.2] [Reference Citation Analysis]
459 Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM, Lee HG, Yoon SK. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57:1244-1250. [PMID: 22824821 DOI: 10.1016/j.jhep.2012.07.017] [Cited by in Crossref: 135] [Cited by in F6Publishing: 141] [Article Influence: 13.5] [Reference Citation Analysis]
460 Sacco R, Antonucci M, Bargellini I, Marceglia S, Mismas V, Cabibbo G. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice? Future Oncology 2015;11:2371-3. [DOI: 10.2217/fon.15.173] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
461 Gomes AS, Rosove MH, Rosen PJ, Amado RG, Sayre JW, Monteleone PA, Busuttil RW. Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients. AJR Am J Roentgenol. 2009;193:1665-1671. [PMID: 19933662 DOI: 10.2214/ajr.08.1806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
462 Yokoyama K, Anan A, Iwata K, Nishizawa S, Morihara D, Ueda S, Sakurai K, Iwashita H, Hirano G, Sakamoto M. Limitation of repeated radiofrequency ablation in hepatocellular carcinoma: proposal of a three (times) × 3 (years) index. J Gastroenterol Hepatol. 2012;27:1044-1050. [PMID: 22433056 DOI: 10.1111/j.1440-1746.2012.07134.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
463 Omyła-Staszewska J, Deptała A. Effective therapeutic management of hepatocellular carcinoma - on the basis of a clinical case. Contemp Oncol (Pozn) 2012;16:60-3. [PMID: 23788857 DOI: 10.5114/wo.2012.27339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
464 Lubel JS, Roberts SK, Strasser SI, Thompson AJ, Philip J, Goodwin M, Clarke S, Crawford DH, Levy MT, Shackel N. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust 2021;214:475-83. [PMID: 33314233 DOI: 10.5694/mja2.50885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
465 Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453-459. [PMID: 19065676 DOI: 10.1002/hep.22648] [Cited by in Crossref: 301] [Cited by in F6Publishing: 274] [Article Influence: 23.2] [Reference Citation Analysis]
466 Hourmand-Ollivier I, Chiche L. [Treatment of hepatocellular carcinoma in the cirrhotic liver]. J Chir (Paris) 2004;141:71-83. [PMID: 15133430 DOI: 10.1016/s0021-7697(04)95574-3] [Reference Citation Analysis]
467 Liu P, Yang J, Niu W, Xie F, Wang Y, Zhou Y. Surgical treatment of huge hepatocellular carcinoma in the caudate lobe. Surg Today. 2011;41:520-525. [PMID: 21431485 DOI: 10.1007/s00595-009-4313-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
468 Mollbrink A, Augsten M, Hultcrantz R, Eriksson LC, Stål P. Sorafenib prolongs liver regeneration after hepatic resection in rats. J Surg Res 2013;184:847-54. [PMID: 23726434 DOI: 10.1016/j.jss.2013.04.062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
469 Liang B, Jia C, Huang Y, He H, Li J, Liao H, Liu X, Liu X, Bai X, Yang D. TPX2 Level Correlates with Hepatocellular Carcinoma Cell Proliferation, Apoptosis, and EMT. Dig Dis Sci 2015;60:2360-72. [PMID: 26025609 DOI: 10.1007/s10620-015-3730-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
470 Liao R, Zhang XD, Li GZ, Qin KL, Yan X. Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin vs. tegafur plus pirarubicin for unresectable hepatocellular carcinoma. J Gastrointest Oncol 2020;11:747-59. [PMID: 32953158 DOI: 10.21037/jgo-20-59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
471 Yang B, Zheng B, Yang M, Zeng Z, Yang F, Pu J, Li C, Liao Z. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. Hepatol Int 2018;12:417-28. [DOI: 10.1007/s12072-018-9888-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
472 Zhao H, Zhai X, Chen Z, Wan X, Chen L, Shen F, Ling C. Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma. Oncotarget 2017;8:45234-41. [PMID: 28423370 DOI: 10.18632/oncotarget.16804] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
473 Igaki H, Nakagawa K, Shiraishi K, Shiina S, Kokudo N, Terahara A, Yamashita H, Sasano N, Omata M, Ohtomo K. Three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava invasion. Jpn J Clin Oncol. 2008;38:438-444. [PMID: 18495749 DOI: 10.1093/jjco/hyn038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
474 Timm S, Sotiropoulos G, Draier M, Knüpffer J, Steger U, Lang H. Selective Transarterial Chemoembolization of Advanced Hepatocellular Carcinomas: A Reasonable Palliative Option. Transplantation Proceedings 2008;40:3179-81. [DOI: 10.1016/j.transproceed.2008.08.074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
475 Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther. 2009;9:503-509. [PMID: 19374603 DOI: 10.1586/era.09.6] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 5.4] [Reference Citation Analysis]
476 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
477 Lei KF, Liu TK, Tsang NM. Towards a high throughput impedimetric screening of chemosensitivity of cancer cells suspended in hydrogel and cultured in a paper substrate. Biosens Bioelectron 2018;100:355-60. [PMID: 28946107 DOI: 10.1016/j.bios.2017.09.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
478 Sato M, Tateishi R, Yasunaga H, Horiguchi H, Yoshida H, Matsuda S, Koike K. Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. J Gastroenterol 2012;47:1125-33. [DOI: 10.1007/s00535-012-0569-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 7.2] [Reference Citation Analysis]
479 Fouad M, Abdel-Rahman O. Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature. Arab J Gastroenterol 2015;16:40-5. [PMID: 25910573 DOI: 10.1016/j.ajg.2015.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
480 Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013;268:431-439. [PMID: 23616632 DOI: 10.1148/radiol.13121637] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
481 Zhao R, Zhou J, Wei Y, Liu F, Chen K, Li Q, Li B. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2017;16:493-8. [DOI: 10.1016/s1499-3872(17)60009-2] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
482 Schiavon LL, Ejima FH, Menezes MR, Bittencourt PL, Moreira AM, Farias AQ, Chagas AL, Assis AM, Mattos ÂZ, Salomão BC, Terra C, Martins FPB, Carnevale FC, Rezende GFDM, Paulo GA, Pereira GHS, Leal Filho JMDM, Meneses J, Costa LSND, Carneiro MV, Álvares-DA-Silva MR, Soares MVA, Pereira OI, Ximenes RO, Durante RFS, Ferreira VA, Lima VM; Members of the Pannel of the 1st Joint Meeting of the SBH, SOBED and SOBRICE. RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE). Arq Gastroenterol 2019;56:213-31. [PMID: 31460590 DOI: 10.1590/S0004-2803.201900000-42] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
483 Kaplan DE. A Matter of TACEte: Plain Vanilla or Combination? Dig Dis Sci 2020;65:934-6. [PMID: 31451983 DOI: 10.1007/s10620-019-05793-2] [Reference Citation Analysis]
484 Zhao Y, Kong LX, Feng FS, Yang J, Wei G. A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study. BMC Cancer 2022;22:311. [PMID: 35321670 DOI: 10.1186/s12885-022-09433-3] [Reference Citation Analysis]
485 Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 2011;9:50-63. [PMID: 21726833 DOI: 10.1016/j.stem.2011.06.005] [Cited by in Crossref: 398] [Cited by in F6Publishing: 378] [Article Influence: 39.8] [Reference Citation Analysis]
486 Zaydfudim V, Smoot RL, Clark CJ, Kendrick ML, Que FG, Farnell MB, Nagorney DM. Role of operative therapy in non-cirrhotic patients with metastatic hepatocellular carcinoma. J Gastrointest Surg 2012;16:1516-23. [PMID: 22644447 DOI: 10.1007/s11605-012-1918-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
487 He M, Cao XC, He GC, Sheng XF, Ai XH, Wu YH. Casticin inhibits epithelial-mesenchymal transition of liver cancer stem cells of the SMMC-7721 cell line through downregulating Twist. Oncol Lett 2014;7:1625-31. [PMID: 24765190 DOI: 10.3892/ol.2014.1899] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
488 Lv Z, Zhang M, Bi J, Xu F, Hu S, Wen J. Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma. Am J Clin Pathol. 2006;125:740-746. [PMID: 16707376 DOI: 10.1309/09b452v7r76k7d6k] [Cited by in Crossref: 27] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
489 Sacco R, Tapete G, Simonetti N, Sellitri R, Natali V, Melissari S, Cabibbo G, Biscaglia L, Bresci G, Giacomelli L. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2017;4:105-10. [PMID: 28795053 DOI: 10.2147/JHC.S103661] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
490 Tian Y, Tang B, Wang C, Sun D, Zhang R, Luo N, Han Z, Liang R, Gao Z, Wang L. Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. Oncotarget 2016;7:46230-41. [PMID: 27323827 DOI: 10.18632/oncotarget.10079] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
491 Geier A, Schadde E, Müllhaupt B. [Current therapeutic strategies for hepatocellular carcinoma]. MMW Fortschr Med 2012;154:63-7; quiz 68-9. [PMID: 22957387 DOI: 10.1007/s15006-012-0931-4] [Reference Citation Analysis]
492 Kim AY, Rhim H, Park M, Lee MW, Kim YS, Choi D, Lim HK. Venous thrombosis after radiofrequency ablation for hepatocellular carcinoma. AJR Am J Roentgenol. 2011;197:1474-1480. [PMID: 22109305 DOI: 10.2214/ajr.11.6495] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 1.9] [Reference Citation Analysis]
493 Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular Carcinoma: Current Management and Perspectives for the Future. Annals of Surgery 2011;253:453-69. [DOI: 10.1097/sla.0b013e31820d944f] [Cited by in Crossref: 282] [Cited by in F6Publishing: 170] [Article Influence: 25.6] [Reference Citation Analysis]
494 Bower M, Metzger T, Robbins K, Tomalty D, Válek V, Boudný J, Andrasina T, Tatum C, Martin RC. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB s. 2010;12:31-36. [PMID: 20495642 DOI: 10.1111/j.1477-2574.2009.00117.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
495 Parikh T, Drew SJ, Lee VS, Wong S, Hecht EM, Babb JS, Taouli B. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology. 2008;246:812-822. [PMID: 18223123 DOI: 10.1148/radiol.2463070432] [Cited by in Crossref: 401] [Cited by in F6Publishing: 353] [Article Influence: 28.6] [Reference Citation Analysis]
496 He T, Zhang L, Kong Y, Huang Y, Zhang Y, Zhou D, Zhou X, Yan Y, Zhang L, Lu S, Zhou J, Wang W. Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis. Int J Oncol 2017;51:1722-30. [PMID: 29075788 DOI: 10.3892/ijo.2017.4175] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
497 Vashist YK, Tiffon C, Stoupis C, Redaelli CA. Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. World J Gastroenterol 2006; 12(42): 6771-6778 [PMID: 17106924 DOI: 10.3748/wjg.v12.i42.6771] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
498 Yao X, Yan D, Jiang X, Li X, Zeng H, Liu D, Li H. Dual-phase Cone-beam CT-based Navigation Imaging Significantly Enhances Tumor Detectability and Aids Superselective Transarterial Chemoembolization of Liver Cancer. Acad Radiol. 2018;25:1031-1037. [PMID: 29398432 DOI: 10.1016/j.acra.2017.12.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
499 Sánchez AIP, Roces LV, García IZ, López EL, Hernandez MAC, Parejo MIB, Peña-Díaz J. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett 2018;15:8863-70. [PMID: 29805623 DOI: 10.3892/ol.2018.8400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
500 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
501 Maeda N, Osuga K, Mikami K, Higashihara H, Onishi H, Nakaya Y, Tatsumi M, Hori M, Kim T, Tomoda K, Nakamura H. Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma. Radiat Med 2008;26:206-12. [DOI: 10.1007/s11604-007-0216-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
502 Rich NE, Yopp AC, Singal AG. Medical Management of Hepatocellular Carcinoma. JOP 2017;13:356-64. [DOI: 10.1200/jop.2017.022996] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 4.4] [Reference Citation Analysis]
503 Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, Mamone G, Vizzini G, Luca A, Gridelli B. Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. World J Gastroenterol 2007;13:6022-6. [PMID: 18023093 DOI: 10.3748/wjg.v13.45.6022] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
504 Hemming AW, Berumen J, Mekeel K. Hepatitis B and Hepatocellular Carcinoma. Clin Liver Dis. 2016;20:703-720. [PMID: 27742009 DOI: 10.1016/j.cld.2016.06.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
505 Kamimura K, Suda T, Tamura Y, Takamura M, Yokoo T, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, Aoyagi Y. Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. BMC Gastroenterol 2012;12:127. [PMID: 22994941 DOI: 10.1186/1471-230X-12-127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
506 Ko HK, Ko GY, Yoon HK, Sung KB. Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. Korean J Radiol. 2007;8:320-327. [PMID: 17673843 DOI: 10.3348/kjr.2007.8.4.320] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
507 Liang HY, Guo QY, Sun W, Mao XN, Wen F, Shan M, Zhao G, Wang XH, Lu ZM. Sequential Use of Transhepatic Arterial Chemoembolization and Bipolar Radiofrequency Ablation in the Clinical Therapy of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2015;30:427-32. [PMID: 26683133 DOI: 10.1089/cbr.2015.1884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
508 Aebersold DM. Potential and future strategies for radiotherapy in hepatocellular carcinoma. Liver Int 2009;29:145-6. [PMID: 19192174 DOI: 10.1111/j.1478-3231.2008.01899.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
509 Masaki T, Morishita A, Kurokohchi K, Kuriyama S. Multidisciplinary treatment of patients with hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;6:1377-84. [DOI: 10.1586/14737140.6.10.1377] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
510 Anestopoulos I, Voulgaridou GP, Georgakilas AG, Franco R, Pappa A, Panayiotidis MI. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacol Ther. 2015;145:103-119. [PMID: 25205159 DOI: 10.1016/j.pharmthera.2014.09.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
511 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol 2015; 21(12): 3462-3471 [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
512 Chan KM, Wu TH, Cheng CH, Lee CF, Wu TJ, Chou HS, Lee WC. Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan. Cancer Manag Res 2019;11:1013-21. [PMID: 30774429 DOI: 10.2147/CMAR.S186678] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
513 Wang MD, Wu H, Fu GB, Zhang HL, Zhou X, Tang L, Dong LW, Qin CJ, Huang S, Zhao LH, Zeng M, Wu MC, Yan HX, Wang HY. Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients. Hepatology 2016;63:1272-86. [PMID: 26698170 DOI: 10.1002/hep.28415] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 8.8] [Reference Citation Analysis]
514 Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Ogura T, Hagihara A, Iwasa S. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization. Cancer Chemother Pharmacol 2008;61:683-8. [DOI: 10.1007/s00280-007-0523-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
515 Zhao M, Xiang P, Jiang H. TransArterial ChemoEmbolization (TACE) with platinum versus anthracyclines for hepatocellular carcinoma: A meta-analysis. Int J Surg 2018;53:151-8. [PMID: 29602011 DOI: 10.1016/j.ijsu.2018.03.049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
516 Peng J, Kang S, Ning Z, Deng H, Shen J, Xu Y, Zhang J, Zhao W, Li X, Gong W, Huang J, Liu L. Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging. Eur Radiol. 2020;30:413-424. [PMID: 31332558 DOI: 10.1007/s00330-019-06318-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]
517 Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol. 2013;36:706-713. [PMID: 22996589 DOI: 10.1007/s00270-012-0476-z] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
518 Chai NX, Chapiro J. Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. Semin Intervent Radiol 2020;37:456-65. [PMID: 33328701 DOI: 10.1055/s-0040-1719186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
519 Fatourou EM, Tsochatzis EA. ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. Hepatobiliary Surg Nutr 2014;3:415-8. [PMID: 25568865 DOI: 10.3978/j.issn.2304-3881.2014.07.01] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
520 Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol 2021;44:1851-67. [PMID: 34694454 DOI: 10.1007/s00270-021-02968-1] [Reference Citation Analysis]
521 Choi TW, Kim HC, Lee JH, Yu SJ, Kang B, Hur S, Lee M, Jae HJ, Chung JW. The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas. Korean J Radiol. 2015;16:1283-1293. [PMID: 26576118 DOI: 10.3348/kjr.2015.16.6.1283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
522 Koom WS, Seong J, Han KH, Lee do Y, Lee JT. Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas? Int J Radiat Oncol Biol Phys. 2010;77:1433-1440. [PMID: 19896779 DOI: 10.1016/j.ijrobp.2009.07.1676] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
523 Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol. 2013;13:60. [PMID: 23566041 DOI: 10.1186/1471-230x-13-60] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 8.3] [Reference Citation Analysis]
524 Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-radosavljevic M, Sieghart W. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. Journal of Hepatology 2014;61:1287-96. [DOI: 10.1016/j.jhep.2014.07.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 10.0] [Reference Citation Analysis]
525 Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Maeda H, Matsuo K, Nishida N, Aramaki T, Anai H, Koura S, Oikawa S, Watanabe K, Yasumoto T, Furuichi K, Yamaguchi M. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol 2014;32:260-5. [PMID: 24615165 DOI: 10.1007/s11604-014-0298-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
526 Zhao T, Tang H, Xie L, Zheng Y, Ma Z, Sun Q, Li X. Scutellaria baicalensis Georgi. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. J Pharm Pharmacol 2019;71:1353-69. [PMID: 31236960 DOI: 10.1111/jphp.13129] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 24.0] [Reference Citation Analysis]
527 Bruix J. HCC surveillance: Who is the target population? Hepatology 2003;37:507-9. [DOI: 10.1053/jhep.2003.50142] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
528 Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon 2012;12:e7635. [PMID: 23233865 DOI: 10.5812/hepatmon.7635] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
529 Perry JF, Strasser SI, George J, Farrell GC, Mccaughan GW. Pharmacotherapy of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2005;4:2175-85. [DOI: 10.1517/14656566.4.12.2175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
530 Lee YK, Jung KS, Kim DY, Choi JY, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim GM. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. J Gastroenterol Hepatol. 2017;32:487-496. [PMID: 27503585 DOI: 10.1111/jgh.13501] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
531 Hayashi PH, Ludkowski M, Forman LM, Osgood M, Johnson S, Kugelmas M, Trotter JF, Bak T, Wachs M, Kam I. Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant. 2004;4:782-787. [PMID: 15084175 DOI: 10.1111/j.1600-6143.2004.00413.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 3.6] [Reference Citation Analysis]
532 Riemsma RP, Bala M, Wolff R, Kleijnen J, Riemsma RP. Percutaneous ethanol injection for liver metastases. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd008717] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
533 Lee EW, Alanis L, Cho SK, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol. 2016;17:472-488. [PMID: 27390539 DOI: 10.3348/kjr.2016.17.4.472] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
534 Schwartz JD, Llovet JM. Molecular Targeting in Hepatocellular Carcinoma. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 165-210. [DOI: 10.1007/978-1-59745-337-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
535 Shen J, Wang WS, Zhu XL, Ni CF. High Epithelial Cell Adhesion Molecule-Positive Circulating Tumor Cell Count Predicts Poor Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization. J Vasc Interv Radiol. 2018;29:1678-1684. [PMID: 30392801 DOI: 10.1016/j.jvir.2018.07.030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
536 Tanaka M, Ando E, Simose S, Hori M, Kuraoka K, Ohno M, Yutani S, Harada K, Sata M. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma. Hepatol Res. 2014;44:194-200. [PMID: 23521520 DOI: 10.1111/hepr.12100] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
537 Guiu B, Minello A, Cottet V, Lepage C, Hillon P, Faivre J, Bouvier A. A 30-Year, Population-Based Study Shows Improved Management and Prognosis of Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2010;8:986-91. [DOI: 10.1016/j.cgh.2010.07.018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
538 Breunig IM, Shaya FT, Hanna N, Seal B, Chirikov VV, Daniel Mullins C. Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. Value Health. 2013;16:760-768. [PMID: 23947969 DOI: 10.1016/j.jval.2013.03.1630] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
539 Gans JH, Lipman J, Golowa Y, Kinkhabwala M, Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Seminars in Nuclear Medicine 2019;49:170-81. [DOI: 10.1053/j.semnuclmed.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
540 Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:1343-1350. [PMID: 22486716 DOI: 10.1111/j.1365-2036.2012.05089.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
541 Chen L, Sun T, Kan X, Chen S, Ren Y, Cao Y, Yan L, Liang B, Xiong B, Zheng C. Transarterial chemoembolization combined with iodine-125 seed implantation for patients with hepatocellular carcinoma: a retrospective controlled study. J Int Med Res 2020;48:300060520944309. [PMID: 33050765 DOI: 10.1177/0300060520944309] [Reference Citation Analysis]
542 Khan N, Bammidi S, Chattopadhyay S, Jayandharan GR. Combination Suicide Gene Delivery with an Adeno-Associated Virus Vector Encoding Inducible Caspase-9 and a Chemical Inducer of Dimerization Is Effective in a Xenotransplantation Model of Hepatocellular Carcinoma. Bioconjug Chem 2019;30:1754-62. [PMID: 31181889 DOI: 10.1021/acs.bioconjchem.9b00291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
543 Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ, Wang QJ, Huang LX, He J, Chen SP, Ke ML, Wu PH, Chen MS, Li SP, Xia JC, Zeng YX. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20:4305-4311. [PMID: 23892527 DOI: 10.1245/s10434-013-3144-x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 6.1] [Reference Citation Analysis]
544 Lu W, Jin XL, Yang C, Du P, Jiang FQ, Ma JP, Yang J, Xie P, Zhang Z. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. Cancer Biol Ther. 2017;18:433-438. [PMID: 28548587 DOI: 10.1080/15384047.2017.1323589] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
545 Gao J, Zhen R, Liao H, Zhuang W, Guo W. Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma. Oncol Lett. 2018;15:7175-7181. [PMID: 29725440 DOI: 10.3892/ol.2018.8242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
546 Welker M, Zangos S, Kriener S, Mönch C, Zeuzem S, Trojan J. Sequential Therapy of Transarterial Chemoembolisation and Sorafenib in Intermediate Stage Hepatocellular Carcinoma. J Gastrointest Canc 2010;41:149-52. [DOI: 10.1007/s12029-010-9146-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
547 Yu S, Estess A, Harris W, Dillon J. A Rare Occurrence of Hepatocellular Carcinoma Metastasis to the Mandible: Report of a Case and Review of the Literature. Journal of Oral and Maxillofacial Surgery 2012;70:1219-23. [DOI: 10.1016/j.joms.2012.01.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
548 Sun Z, Zhao Z, Li G, Dong S, Huang Z, Ye L, Liang H, Qu J, Ai X, Zhang W, Chen X. Relevance of Two Genes in the Multidrug Resistance of Hepatocellular Carcinoma: In Vivo and Clinical Studies. Tumori 2010;96:90-6. [DOI: 10.1177/030089161009600115] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 9.3] [Reference Citation Analysis]
549 Bannerman D, Wan W. Multifunctional microbeads for drug delivery in TACE. Expert Opinion on Drug Delivery 2016;13:1289-300. [DOI: 10.1080/17425247.2016.1192122] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
550 Aloia TA, Adam R, Samuel D, Azoulay D, Castaing D. A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. J Gastrointest Surg. 2007;11:1328-1332. [PMID: 17682827 DOI: 10.1007/s11605-007-0211-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
551 Huo T, Lee S. Management of inoperable hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:S272-8. [DOI: 10.1111/j.1440-1746.2004.03686.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
552 Van Thai N, Thinh NT, Ky TD, Bang MH, Giang DT, Ha LN, Son MH, Tien DD, Lee HW. Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma. BMC Gastroenterol 2021;21:216. [PMID: 33980171 DOI: 10.1186/s12876-021-01805-6] [Reference Citation Analysis]
553 Ramacciato G, Mercantini P, Petrucciani N, Ravaioli M, Cucchetti A, Del Gaudio M, Cescon M, Ziparo V, Pinna AD. Does Surgical Resection Have a Role in the Treatment of Large or Multinodular Hepatocellular Carcinoma? The American Surgeon 2010;76:1189-97. [DOI: 10.1177/000313481007601116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
554 Wang GZ, Zhang W, Fang ZT, Zhang W, Yang MJ, Yang GW, Li S, Zhu L, Wang LL, Zhang WS, Liu R, Qian S, Wang JH, Qu XD. Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro. J Cancer Res Clin Oncol 2014;140:1125-36. [PMID: 24756364 DOI: 10.1007/s00432-014-1659-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
555 Vadot L, Boulin M, Malbranche C, Guiu B, Aho S, Musat A, Pernot C, Guignard MH, Hillon P, Fagnoni P. Result and cost of hepatic chemoembolisation with drug eluting beads in 21 patients. Diagn Interv Imaging 2013;94:53-9. [PMID: 23146417 DOI: 10.1016/j.diii.2012.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
556 Wang W, Guo Y, Zhong J, Wang Q, Wang X, Wei H, Li J, Xiu P. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Sci Rep 2021;11:2415. [PMID: 33510294 DOI: 10.1038/s41598-021-82058-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
557 Wong RJ, Devaki P, Nguyen L, Cheung R, Nguyen MH. Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry. Liver Transpl. 2014;20:528-535. [PMID: 24415542 DOI: 10.1002/lt.23820] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
558 Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51-69. [PMID: 26020029 DOI: 10.1159/000367728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
559 Lin CT, Hsu KF, Chen TW, Yu JC, Chan DC, Yu CY, Hsieh TY, Fan HL, Kuo SM, Chung KP, Hsieh CB. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg. 2010;34:2155-2161. [PMID: 20407768 DOI: 10.1007/s00268-010-0598-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
560 Reig M, Matilla A, Bustamante J, Castells L, de La Mata M, Delgado M, Moreno JM, Forner A, Varela M. Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma. Gastroenterol Hepatol. 2010;33:741-752. [PMID: 20851505 DOI: 10.1016/j.gastrohep.2010.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
561 Ballardini P, Marri I, Margutti G, Aliberti C, Benea G, Manfredini R. Long-lasting Response with Metronomic Capecitabine in Advanced Hepatocellular Carcinoma. Tumori 2010;96:768-70. [DOI: 10.1177/030089161009600521] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
562 Cao L, Fan X, Jing W, Liang Y, Chen R, Liu Y, Zhu M, Jia R, Wang H, Zhang X, Zhang Y, Zhou X, Zhao J, Guo Y. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway. Oncotarget 2015;6:6627-40. [PMID: 25749383 DOI: 10.18632/oncotarget.3113] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
563 Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee YS, Lee HC. Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma.PLoS One. 2020;15:e0229696. [PMID: 32130270 DOI: 10.1371/journal.pone.0229696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
564 Chen Q, Ayer T, Chhatwal J. Optimal M -Switch Surveillance Policies for Liver Cancer in a Hepatitis C–Infected Population. Operations Research 2018;66:673-96. [DOI: 10.1287/opre.2017.1706] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
565 Han B, Yu YQ, Yang QL, Shen CY, Wang XJ. Kaempferol induces autophagic cell death of hepatocellular carcinoma cells via activating AMPK signaling. Oncotarget 2017;8:86227-39. [PMID: 29156790 DOI: 10.18632/oncotarget.21043] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
566 Liu T, Shao Y, Lu L, Shen Y, Hsu C, Lin Z, Hsu C, Cheng A. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2019;13:615-21. [DOI: 10.1080/17474124.2019.1621165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
567 Mukherjee A, Subramanian S, Ambade R, Avhad B, Dash A, Korde A. Development of Semiautomated Module for Preparation of 131I Labeled Lipiodol for Liver Cancer Therapy. Cancer Biother Radiopharm 2017;32:33-7. [PMID: 28128645 DOI: 10.1089/cbr.2016.2088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
568 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
569 Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, Valla D, Farges O, Degos F. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 2010;22:1106-1110. [PMID: 20300004 DOI: 10.1097/meg.0b013e3283386053] [Cited by in Crossref: 51] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
570 Lin J, Wu L, Bai X, Xie Y, Wang A, Zhang H, Yang X, Wan X, Lu X, Sang X, Zhao H. Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget 2016;7:71036-51. [PMID: 27626176 DOI: 10.18632/oncotarget.11954] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
571 Jafri S, Gordon SC. Care of the Cirrhotic Patient. Infectious Disease Clinics of North America 2012;26:979-94. [DOI: 10.1016/j.idc.2012.08.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
572 Lee JW, Yun M, Cho A, Han KH, Kim DY, Lee SM, Lee JD. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. Ann Nucl Med. 2015;29:400-408. [PMID: 25652647 DOI: 10.1007/s12149-015-0956-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
573 Bock B, Hasdemir D, Wandrer F, Rodt T, Manns MP, Schulze-Osthoff K, Bantel H. Serum cell death biomarker mirrors liver cancer regression after transarterial chemoembolisation. Aliment Pharmacol Ther 2016;44:747-54. [PMID: 27485159 DOI: 10.1111/apt.13758] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
574 Jia H, Yang Q, Wang T, Cao Y, Jiang QY, Ma HD, Sun HW, Hou MX, Yang YP, Feng F. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents. Biochim Biophys Acta 2016;1860:1417-30. [PMID: 27091611 DOI: 10.1016/j.bbagen.2016.04.007] [Cited by in Crossref: 51] [Cited by in F6Publishing: 68] [Article Influence: 8.5] [Reference Citation Analysis]
575 Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914-921. [PMID: 18177453 DOI: 10.1111/j.1572-0241.2007.01712.x] [Cited by in Crossref: 258] [Cited by in F6Publishing: 267] [Article Influence: 18.4] [Reference Citation Analysis]
576 Burak KW, Kneteman NM. An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol 2010;24:643-50. [PMID: 21157578 DOI: 10.1155/2010/410574] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
577 Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108:1252-1259. [PMID: 23449352 DOI: 10.1038/bjc.2013.85] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 8.9] [Reference Citation Analysis]
578 Wang EA, Stein JP, Bellavia RJ, Broadwell SR. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract 2017;71:e12972. [DOI: 10.1111/ijcp.12972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
579 Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009;25:186-194. [PMID: 19387255 DOI: 10.1097/mog.0b013e32832962a1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 51] [Article Influence: 7.8] [Reference Citation Analysis]
580 Han KN, Kim YT, Yoon JH, Suh KS, Song JY, Kang CH, Sung SW, Kim JH. Role of surgical resection for pulmonary metastasis of hepatocellular carcinoma. Lung Cancer. 2010;70:295-300. [PMID: 20353879 DOI: 10.1016/j.lungcan.2010.02.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
581 He C, Zhang Y, Lin X. Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis. J Gastrointest Surg 2018;22:989-97. [PMID: 29435900 DOI: 10.1007/s11605-018-3703-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
582 Eriguchi T, Tsukamoto N, Kuroiwa N, Nemoto T, Ogata T, Okubo Y, Nakano S, Sugawara A. Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Pract Radiat Oncol 2021;11:44-52. [PMID: 32791232 DOI: 10.1016/j.prro.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
583 Herman JM, Pawlik TM. Hepatocellular Carcinoma, Gallbladder Cancer, and Cholangiocarcinoma. In: Lu JJ, Brady LW, editors. Radiation Oncology. Berlin: Springer Berlin Heidelberg; 2008. pp. 221-43. [DOI: 10.1007/978-3-540-77385-6_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
584 Chingkoe CM, Chang SD, Legiehn GM, Weiss A. Hepatic artery pseudoaneurysms arising from within a hepatocellular carcinoma. Br J Radiol 2010;83:e252-4. [PMID: 21088082 DOI: 10.1259/bjr/55365425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
585 Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Vitali M, Bertuzzo F, De Angelis M, Mantovani G, Iacono C. Hepatocellular carcinoma: Surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J Gastroenterol 2014; 20(24): 7525-7533 [PMID: 24976693 DOI: 10.3748/wjg.v20.i24.7525] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
586 Malagari K. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. Expert Rev Anticancer Ther. 2008;8:1643-1650. [PMID: 18925855 DOI: 10.1586/14737140.8.10.1643] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
587 Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 2013;33:327-337. [PMID: 23331661 DOI: 10.1111/liv.12083] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
588 Azad A, Chionh F, Cebon J. Targeted agents for the systemic treatment of advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology 2009;5:76-86. [DOI: 10.1111/j.1743-7563.2009.01202.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
589 Musch A, Rabe C, Paik MD, Berna MJ, Schmitz V, Hoffmann P, Nischalke HD, Sauerbruch T, Caselmann WH. Altered expression of TGF-beta receptors in hepatocellular carcinoma--effects of a constitutively active TGF-beta type I receptor mutant. Digestion 2005;71:78-91. [PMID: 15775675 DOI: 10.1159/000084523] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
590 Mouli SK, Goff LW. Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. Curr Treat Options in Oncol 2017;18. [DOI: 10.1007/s11864-017-0509-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
591 Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot F, Roumilhac D, Canva V, Paris J, Chaput J, Naveau S. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma: META-ANALYSIS: ADJUVANT THERAPY AFTER CURATIVE LIVER RESECTION FOR HCC. Alimentary Pharmacology & Therapeutics 2003;17:1247-61. [DOI: 10.1046/j.1365-2036.2003.01580.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 4.0] [Reference Citation Analysis]
592 Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, Sharma R, ElTawil R, Kwon D, Venkat S, Portelance L, Yechieli R. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. 2016;39:1580-1588. [PMID: 27586657 DOI: 10.1007/s00270-016-1426-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 8.3] [Reference Citation Analysis]
593 Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clin Imaging 2021;76:123-9. [PMID: 33592550 DOI: 10.1016/j.clinimag.2021.01.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
594 Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014;11:209-19. [PMID: 24247262 DOI: 10.1038/nrgastro.2013.216] [Cited by in Crossref: 155] [Cited by in F6Publishing: 137] [Article Influence: 17.2] [Reference Citation Analysis]
595 Yin X, Zhang L, Wang YH, Zhang BH, Gan YH, Ge NL, Chen Y, Li LX, Ren ZG. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. BMC Cancer. 2014;14:849. [PMID: 25409554 DOI: 10.1186/1471-2407-14-849] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
596 Song DS, Bae SH, Song MJ, Lee SW, Kim HY, Lee YJ, Oh JS, Chun HJ, Lee HG, Choi JY, Yoon SK. Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2013; 19(29): 4679-4688 [PMID: 23922465 DOI: 10.3748/wjg.v19.i29.4679] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
597 Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015;61:184-90. [DOI: 10.1002/hep.27443] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 10.9] [Reference Citation Analysis]
598 Karani JB, Yu DF, Kane PA. Interventional Radiology in Liver Transplantation. Cardiovasc Intervent Radiol 2005;28:271-83. [DOI: 10.1007/s00270-004-0074-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
599 Huang YH, Chen CH, Chang TT, Chen SC, Wang SY, Lee PC, Lee HS, Lin PW, Huang GT, Sheu JC. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. Liver Int. 2004;24:419-424. [PMID: 15482337 DOI: 10.1111/j.1478-3231.2004.0941.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
600 Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podesta E, Romagnoli P. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569. [PMID: 12823161 DOI: 10.1046/j.1365-2036.2003.01647.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
601 Watanabe H, Kanematsu M, Goshima S, Kondo H, Kajita K, Kawada H, Noda Y, Moriyama N. Detection of focal hepatic lesions with 3-T MRI: comparison of two-dimensional and three-dimensional T2-weighted sequences. Jpn J Radiol 2012;30:721-8. [DOI: 10.1007/s11604-012-0111-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
602 Wang K, Mao Z, Liu L, Zhang R, Liang Q, Xiong Y, Yuan W, Wei L. Rab17 inhibits the tumourigenic properties of hepatocellular carcinomas via the Erk pathway. Tumour Biol 2015;36:5815-24. [PMID: 25707355 DOI: 10.1007/s13277-015-3251-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
603 Sangro B. Refined tools for the treatment of hepatocellular carcinoma. J Hepatol 2005;42:629-31. [PMID: 15826709 DOI: 10.1016/j.jhep.2005.02.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
604 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1689] [Article Influence: 289.2] [Reference Citation Analysis]
605 Kim H, Chung JW, Choi SH, Jae HJ, Lee W, Park JH. Internal Mammary Arteries Supplying Hepatocellular Carcinoma: Vascular Anatomy at Digital Subtraction Angiography in 97 Patients. Radiology 2007;242:925-32. [DOI: 10.1148/radiol.2423060220] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
606 Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, Osaki Y, Sata M, Fujiyama S, Kumada T. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2009;51:1030-1036. [PMID: 19864035 DOI: 10.1016/j.jhep.2009.09.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
607 Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25. [PMID: 17103105 DOI: 10.1007/s00270-006-0062-3] [Cited by in Crossref: 564] [Cited by in F6Publishing: 526] [Article Influence: 37.6] [Reference Citation Analysis]
608 Maeda N, Osuga K, Higashihara H, Tomoda K, Mikami K, Nakazawa T, Nakamura H, Tomiyama N. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion. Cardiovasc Intervent Radiol. 2012;35:82-89. [PMID: 21203761 DOI: 10.1007/s00270-010-0086-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
609 Granito A, Bolondi L. Medical treatment of hepatocellular carcinoma. Mediterr J Hematol Infect Dis 2009;1:e2009021. [PMID: 21415957 DOI: 10.4084/MJHID.2009.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
610 Nagamatsu H, Hiraki M, Mizukami N, Yoshida H, Iwamoto H, Sumie S, Torimura T, Sata M. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther. 2010;32:543-550. [PMID: 20500734 DOI: 10.1111/j.1365-2036.2010.04379.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
611 Zhang Y, Zhang M, Chen M, Mei J, Xu L, Guo R, Lin X, Li J, Peng Z. Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. JAMA Netw Open 2018;1:e183213. [PMID: 30646226 DOI: 10.1001/jamanetworkopen.2018.3213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
612 Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015;15:392. [PMID: 25957784 DOI: 10.1186/s12885-015-1373-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
613 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer. 2011;11:202. [PMID: 21615953 DOI: 10.1186/1471-2407-11-202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
614 Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:1437-1444. [PMID: 19486255 DOI: 10.1111/j.1440-1746.2009.05863.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
615 Martin SP, Fako V, Dang H, Dominguez DA, Khatib S, Ma L, Wang H, Zheng W, Wang XW. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:99. [PMID: 32487192 DOI: 10.1186/s13046-020-01605-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
616 Zhou C, Shi Q, Liu J, Huang S, Yang C, Xiong B. Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel. J Hepatocell Carcinoma 2020;7:447-56. [PMID: 33409168 DOI: 10.2147/JHC.S282209] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
617 Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, Morris DL. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int. 2010;30:166-174. [PMID: 19912531 DOI: 10.1111/j.1478-3231.2009.02166.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
618 Sherman M, Takayama Y. Screening and treatment for hepatocellular carcinoma. Gastroenterology Clinics of North America 2004;33:671-91. [DOI: 10.1016/j.gtc.2004.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
619 Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB, Carr BI, Gamblin TC. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): A single-institution experience. Journal of Gastrointestinal Surgery. 2008;12:129-137. [PMID: 17851723 DOI: 10.1007/s11605-007-0312-y] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 5.8] [Reference Citation Analysis]
620 Qiao CX, Zhai XF, Ling CQ, Lang QB, Dong HJ, Liu Q, Li MD. Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma. World J Gastroenterol 2012; 18(21): 2689-2694 [PMID: 22690079 DOI: 10.3748/wjg.v18.i21.2689] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
621 Husseini F, Delord JP, Fournel-Federico C, Guitton J, Erbs P, Homerin M, Halluard C, Jemming C, Orange C, Limacher JM, Kurtz JE. Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine. Ann Oncol 2017;28:169-74. [PMID: 28177438 DOI: 10.1093/annonc/mdw440] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
622 Tsochatzis EA, Fatourou EM, Triantos CK, Burroughs AK. Transarterial therapies for hepatocellular carcinoma. Recent Results Cancer Res 2013;190:195-206. [PMID: 22941022 DOI: 10.1007/978-3-642-16037-0_13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
623 Lee M, Chuang VP, Wei C, Cheng T, Cherng M. Histopathologic correlation of hepatocellular carcinoma after transcatheter arterial chemoembolization with polyvinyl alcohol particle of various sizes. European Journal of Radiology 2012;81:1976-9. [DOI: 10.1016/j.ejrad.2011.05.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
624 Gai X, Zhou P, Xu M, Liu Z, Zheng X, Liu Q. Hyperactivation of IL-6/STAT3 pathway leaded to the poor prognosis of post-TACE HCCs by HIF-1α/SNAI1 axis-induced epithelial to mesenchymal transition. J Cancer 2020;11:570-82. [PMID: 31942180 DOI: 10.7150/jca.35631] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
625 Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016;64:106-116. [PMID: 26765068 DOI: 10.1002/hep.28453] [Cited by in Crossref: 226] [Cited by in F6Publishing: 208] [Article Influence: 37.7] [Reference Citation Analysis]
626 Rai V, Mukherjee S. Targets of immunotherapy for hepatocellular carcinoma: An update. World J Hepatol 2022; 14(1): 140-157 [DOI: 10.4254/wjh.v14.i1.140] [Reference Citation Analysis]
627 Chen X, Liu L, Pan X. Portal vein tumor thrombus in advanced hepatocellular carcinoma: A case report. Oncol Lett 2015;9:2495-8. [PMID: 26137096 DOI: 10.3892/ol.2015.3115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
628 Zhu D, Li Y, Zhang Z, Xue Z, Hua Z, Luo X, Zhao T, Lu C, Liu Y. Recent advances of nanotechnology-based tumor vessel-targeting strategies. J Nanobiotechnology 2021;19:435. [PMID: 34930293 DOI: 10.1186/s12951-021-01190-y] [Reference Citation Analysis]
629 Song JE, Kim DY. Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol 2017; 9(18): 808-814 [PMID: 28706579 DOI: 10.4254/wjh.v9.i18.808] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
630 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015;7:738-52. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Reference Citation Analysis]
631 Ni W, Chen B, Zhou G, Lu C, Xiao M, Guan C, Zhang Y, He S, Shen A, Ni R. Overexpressed nuclear BAG-1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin. J Cell Biochem 2013;114:2120-30. [PMID: 23553841 DOI: 10.1002/jcb.24560] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
632 Meza-Junco J, Montano-Loza AJ, Liu DM, Sawyer MB, Bain VG, Ma M, Owen R. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev 2012;38:54-62. [PMID: 21726960 DOI: 10.1016/j.ctrv.2011.05.002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
633 Sikander A, Sadashiv S, Ronald S, Milind J. Transarterial Chemoembolization in a Patient With Recurrent Hepatocellular Carcinoma and Portal Vein Thrombosis: A Case Report and Review of the Literature. American Journal of Clinical Oncology 2005;28:638-9. [DOI: 10.1097/01.coc.0000158488.36371.50] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
634 Byrne TJ, Rakela J. Loco-regional therapies for patients with hepatocellular carcinoma awaiting liver transplantation: Selecting an optimal therapy. World J Transplant 2016; 6(2): 306-313 [PMID: 27358775 DOI: 10.5500/wjt.v6.i2.306] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
635 Qadan M, Fong ZV, Delman AM, Gabr A, Salem R, Shah SA. Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma. J Gastrointest Surg 2021. [PMID: 34345997 DOI: 10.1007/s11605-021-05095-x] [Reference Citation Analysis]
636 Morimoto M, Numata K, Nozawa A, Kondo M, Nozaki A, Nakano M, Tanaka K. Radiofrequency ablation of the liver: extended effect of transcatheter arterial embolization with iodized oil and gelatin sponge on histopathologic changes during follow-up in a pig model. J Vasc Interv Radiol 2010;21:1716-24. [PMID: 20884228 DOI: 10.1016/j.jvir.2010.06.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
637 Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim M. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int 2014;34:305-12. [DOI: 10.1111/liv.12270] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
638 Beaton L, Tregidgo HFJ, Znati SA, Forsyth S, Clarkson MJ, Bandula S, Chouhan M, Lowe HL, Zaw Thin M, Hague J, Sharma D, Pollok JM, Davidson BR, Raja J, Munneke G, Stuckey DJ, Bascal ZA, Wilde PE, Cooper S, Ryan S, Czuczman P, Boucher E, Hartley JA, Lewis AL, Jansen M, Meyer T, Sharma RA. VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies. JMIR Res Protoc 2019;8:e13696. [PMID: 31579027 DOI: 10.2196/13696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
639 Sinn M, Nicolaou A, Ricke J, Podrabsky P, Seehofer D, Gebauer B, Pech M, Neuhaus P, Dörken B, Riess H, Hildebrandt B. Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161). BMC Gastroenterol 2013;13:125. [PMID: 23927554 DOI: 10.1186/1471-230X-13-125] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
640 Han G, Yang J, Shao G, Teng G, Wang M, Yang J, Liu Z, Feng G, Yang R, Lu L. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol. 2013;9:403-410. [PMID: 23469975 DOI: 10.2217/fon.13.11] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
641 Kis B, El-Haddad G, Sheth RA, Parikh NS, Ganguli S, Shyn PB, Choi J, Brown KT. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729244. [PMID: 28975829 DOI: 10.1177/1073274817729244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
642 Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy. American Journal of Roentgenology 2013;201:80-96. [DOI: 10.2214/ajr.13.10706] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 5.9] [Reference Citation Analysis]
643 Forner A, Real MI, Varela M, Bruix J. Transarterial chemoembolization for patients with hepatocellular carcinoma. Hepatology Research 2007;37:S230-7. [DOI: 10.1111/j.1872-034x.2007.00190.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
644 Wang J, Changchien C, Hu T, Lee C, Kee K, Lin C, Chen C, Chen T, Huang Y, Lu S. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma – Survival analysis of 3892 patients. European Journal of Cancer 2008;44:1000-6. [DOI: 10.1016/j.ejca.2008.02.018] [Cited by in Crossref: 142] [Cited by in F6Publishing: 147] [Article Influence: 10.1] [Reference Citation Analysis]
645 Meyer BC, Frericks BB, Voges M, Borchert M, Martus P, Justiz J, Wolf KJ, Wacker FK. Visualization of hypervascular liver lesions During TACE: comparison of angiographic C-arm CT and MDCT. AJR Am J Roentgenol. 2008;190:W263-W269. [PMID: 18356419 DOI: 10.2214/ajr.07.2695] [Cited by in Crossref: 57] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
646 Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, Kang JK, Kim SY, Lee DH, Han CJ. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol. 2013;8:250. [PMID: 24160944 DOI: 10.1186/1748-717x-8-250] [Cited by in Crossref: 124] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
647 Liu C, Wu H, Mao Y, Chen W, Chen S. Exosomal microRNAs in hepatocellular carcinoma. Cancer Cell Int 2021;21:254. [PMID: 33964930 DOI: 10.1186/s12935-021-01941-9] [Reference Citation Analysis]
648 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 261] [Article Influence: 37.1] [Reference Citation Analysis]
649 Wang Y, Deng T, Zeng L, Chen W. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis. Hepatol Res. 2016;46:58-71. [PMID: 26265000 DOI: 10.1111/hepr.12568] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
650 White JA, Redden DT, Bryant MK, Dorn D, Saddekni S, Abdel Aal AK, Zarzour J, Bolus D, Smith JK, Gray S, Eckhoff DE, DuBay DA. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. HPB (Oxford) 2014;16:1095-101. [PMID: 25158123 DOI: 10.1111/hpb.12313] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
651 Price TR, Perkins SM, Sandrasegaran K, Henderson MA, Maluccio MA, Zook JE, Tector AJ, Vianna RM, Johnstone PA, Cardenes HR. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer. 2012;118:3191-3198. [PMID: 22025126 DOI: 10.1002/cncr.26404] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 7.8] [Reference Citation Analysis]
652 Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol. 2009;50:604-620. [PMID: 19157625 DOI: 10.1016/j.jhep.2008.12.011] [Cited by in Crossref: 381] [Cited by in F6Publishing: 361] [Article Influence: 27.2] [Reference Citation Analysis]
653 Zhang L, Jiang G, Yao F, Liang G, Wang F, Xu H, Wu Y, Yu X, Liu H. Osthole promotes anti-tumor immune responses in tumor-bearing mice with hepatocellular carcinoma. Immunopharmacol Immunotoxicol 2015;37:301-7. [PMID: 25975579 DOI: 10.3109/08923973.2015.1035391] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
654 Boulin M, Hillon P, Cercueil JP, Bonnetain F, Dabakuyo S, Minello A, Jouve JL, Lepage C, Bardou M, Wendremaire M, Guerard P, Denys A, Grandvuillemin A, Chauffert B, Bedenne L, Guiu B. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther. 2014;39:1301-1313. [PMID: 24738629 DOI: 10.1111/apt.12746] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
655 Bonomo G, Pedicini V, Monfardini L, Della Vigna P, Poretti D, Orgera G, Orsi F. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33:552-559. [PMID: 19957182 DOI: 10.1007/s00270-009-9752-y] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 5.2] [Reference Citation Analysis]
656 Bonekamp S, Bonekamp D, Geschwind JF, Corona-Villalobos CP, Reyes DK, Pawlik TM, Kamel IR. Response stratification and survival analysis of hepatocellular carcinoma patients treated with intra-arterial therapy using MR imaging-based arterial enhancement fraction. J Magn Reson Imaging 2014;40:1103-11. [PMID: 24214827 DOI: 10.1002/jmri.24465] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
657 Choi JW, Kim H, Chung JW, Kim JD, Kim GM, Lee IJ, Jae HJ, Park JH. Chemoembolization Via Branches from the Splenic Artery in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2012;35:90-6. [DOI: 10.1007/s00270-011-0109-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
658 Vogl TJ, Naguib NN, Nour-eldin NA, Rao P, Emami AH, Zangos S, Nabil M, Abdelkader A. Review on transarterial chemoembolization in hepatocellular carcinoma: Palliative, combined, neoadjuvant, bridging, and symptomatic indications. European Journal of Radiology 2009;72:505-16. [DOI: 10.1016/j.ejrad.2008.08.007] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 6.5] [Reference Citation Analysis]
659 Op den Winkel M, Nagel D, Op den Winkel P, Trojan J, Paprottka PM, Steib CJ, Schmidt L, Göller M, Stieber P, Göhring P, Herbst A, Rentsch M, De Toni EN, Göke B, Gerbes AL, Kolligs FT. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score. Eur J Gastroenterol Hepatol 2018;30:44-53. [PMID: 29076939 DOI: 10.1097/MEG.0000000000001005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
660 Wilson GK, Tennant DA, McKeating JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol. 2014;61:1397-1406. [PMID: 25157983 DOI: 10.1016/j.jhep.2014.08.025] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 11.8] [Reference Citation Analysis]
661 Bayle M, Clerc-Urmès I, Ayav A, Bronowicki JP, Petit I, Orry X, Laurent V. Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings. Abdom Radiol (NY) 2019;44:85-94. [PMID: 30054686 DOI: 10.1007/s00261-018-1714-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
662 Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Curr Oncol 2016;23:e605-14. [PMID: 28050151 DOI: 10.3747/co.23.3394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
663 Dufour JF. TACE with or without systemic therapy? J Hepatol. 2012;56:1224-1225. [PMID: 22402292 DOI: 10.1016/j.jhep.2012.02.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
664 Hong K, Liapi E, Georgiades CS, Geschwind JF. Case-controlled comparison of a percutaneous collagen arteriotomy closure device versus manual compression after liver chemoembolization. J Vasc Interv Radiol 2005;16:339-45. [PMID: 15758129 DOI: 10.1097/01.RVI.0000147068.25548.57] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
665 Nörthen A, Asendorf T, Shin HO, Hinrichs JB, Werncke T, Vogel A, Kirstein MM, Wacker FK, Rodt T. Parametric response mapping cut-off values that predict survival of hepatocellular carcinoma patients after TACE. Abdom Radiol (NY). 2018;43:3288-3300. [PMID: 29680967 DOI: 10.1007/s00261-018-1610-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
666 Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T; Miriplatin TACE Study Group. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. J Gastroenterol 2018;53:281-90. [PMID: 28766016 DOI: 10.1007/s00535-017-1374-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
667 Wischhusen JC, Chowdhury SM, Lee T, Wang H, Bachawal S, Devulapally R, Afjei R, Sukumar UK, Paulmurugan R. Ultrasound-mediated delivery of miRNA-122 and anti-miRNA-21 therapeutically immunomodulates murine hepatocellular carcinoma in vivo. J Control Release 2020;321:272-84. [PMID: 32004588 DOI: 10.1016/j.jconrel.2020.01.051] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
668 Xiu P, Dong XF, Li XP, Li J. Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma. World J Gastroenterol 2015; 21(27): 8262-8270 [PMID: 26217078 DOI: 10.3748/wjg.v21.i27.8262] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
669 Slotta JE, Kollmar O, Ellenrieder V, Ghadimi BM, Homayounfar K. Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives. World J Hepatol 2015; 7(9): 1168-1183 [PMID: 26019733 DOI: 10.4254/wjh.v7.i9.1168] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
670 Maio MD, Daniele B, Pignata S, Gallo C, Maio ED, Morabito A, Piccirillo MC, Perrone F. Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroenterol 2008; 14(11): 1682-1689 [PMID: 18350599 DOI: 10.3748/wjg.14.1682] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
671 Guiu B, Colin C, Cercueil J, Loffroy R, Guiu S, Ferrant E, Jouve J, Bonnetain F, Boulin M, Ghiringhelli F, Minello A, Hillon P, Bedenne L, Krause D, Chauffert B. Pilot Study of Transarterial Chemoembolization With Pirarubicin and Amiodarone for Unresectable Hepatocellular Carcinoma. American Journal of Clinical Oncology 2009;32:238-44. [DOI: 10.1097/coc.0b013e3181845529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
672 Shiozawa K, Matsui T, Murakami T, Watanabe M, Maetani I. Predicting Therapeutic Efficacy of Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound. Diagnostics (Basel) 2021;11:291. [PMID: 33673221 DOI: 10.3390/diagnostics11020291] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
673 Elsadek B, Mansour A, Saleem T, Warnecke A, Kratz F. The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib. Digestive and Liver Disease 2017;49:213-22. [DOI: 10.1016/j.dld.2016.10.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
674 Abdel-rahman O, Elsayed ZA. Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature. Dig Dis Sci 2013;58:3389-96. [DOI: 10.1007/s10620-013-2872-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
675 Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. Cardiovasc Intervent Radiol 2022. [PMID: 35119481 DOI: 10.1007/s00270-021-03031-9] [Reference Citation Analysis]
676 Zheng J, Shao G, Luo J. Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib. Clin Transl Oncol. 2014;16:1012-1017. [PMID: 24894839 DOI: 10.1007/s12094-014-1189-3] [Cited by in Crossref: 3]